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ABSTRACT 
Many compounds have a limited ability to penetrate into the central nervous system (CNS) due to the existence 
of sophisticated barrier systems between the CNS and blood. The blood-brain barrier (BBB) between cerebral 
blood and the interstitial fluid of the brain, and the blood-cerebrospinal fluid barrier (BCSFB) between blood and 
ventricular and subarachnoid cerebrospinal fluid (CSF), both act as physical, metabolic and efflux barriers. In 
addition, they express several influx transporters and receptors. As a consequence, the BBB and the BCSFB can 
regulate extremely efficiently the CNS transport of both small and large molecules. The CNS distribution of 
non-steroidal anti-inflammatory drugs (NSAIDs) such as ibuprofen, indomethacin and ketoprofen is of interest, 
because in addition to their well-known peripheral effects, they may also have important central actions. For 
example in children, the central antinociceptive actions of these widely used NSAIDs rationalizes the need for 
understanding their CNS distribution. Furthermore, in adults and the elderly, the long-term use of NSAIDs may 
reduce the risk, or delay the onset of Alzheimer's disease (AD). In order to act at the central level, a sufficient 
amount of a drug must gain access to the CNS. NSAIDs are weak acids and are ionized at the pH of the 
circulation and additionally, they are extensively bound to plasma proteins; two characteristics which may limit 
their CNS permeation.      
 
In the present study, the brain permeation of ibuprofen and indomethacin was determined in rats after 
intravenous infusion. In addition, the effect of plasma protein binding on the brain permeation of indomethacin 
was studied with the in situ brain perfusion technique. The effect of an efflux inhibitor, probenecid, on brain 
permeation of indomethacin was evaluated both after intravenous administration, and after in situ brain perfusion 
method. The CSF distribution of ketoprofen and indomethacin was evaluated in children, aged 4-144 months. 
Children were given ketoprofen or indomethacin intravenously prior to surgery with spinal anaesthesia. 
Simultaneous venous blood and CSF samples were collected once from each child 7-67 minutes after ketoprofen 
administration and 14-225 minutes after indomethacin administration. Drug concentrations were determined in 
CSF, plasma and protein-free plasma, and the concentration ratio between CSF and plasma was calculated. 
 
Brain penetration of both ibuprofen and indomethacin was found to be low in rats, the total brain to plasma ratio 
being less than 0.02. Co-administration of probenecid increased the brain to plasma concentration ratio of 
indomethacin by 2.4-fold. Co-administration of probenecid increased also the unbound indomethacin 
concentration by 6.3-fold. The single point unidirectional transfer constant (Kin) of indomethacin was 2.2 ± 0.2 x 
10-3 ml/s/g brain. The Kin value of indomethacin in the presence of probenecid was 3.7 ± 0.3 x 10-3 ml/s/g brain, 
and 1.9 ± 0.3 x 10-3 and 0.5 ± 0.1 x 10-3 ml/s/g brain after perfusion with a perfusion fluid containing 0.28% and 
2.8 % (w/v) bovine serum albumin, respectively. In children, the CSF to total plasma concentration ratios of both 
ketoprofen and indomethacin remained less than 0.01 at all times. The ketoprofen concentration in the CSF 
ranged from 1.4 to 24 ng/ml (median 6.6 ng/ml) after the dose of 1 mg/kg. The indomethacin concentrations in 
the CSF ranged from 0.2 to 5.0 ng/ml (median 1.4 ng/ml) after a dose of 0.35 mg/kg.  
 
In conclusion, ibuprofen and indomethacin permeated poorly into the rat brain after intravenous administration. 
The efflux protein inhibitor, probenecid, was able to increase the brain permeation of indomethacin. The increase 
in the unbound fraction after co-administration of probenecid may explain the enhanced brain permeation of 
indomethacin after intravenous administration. However, some effect on the efflux systems at the BBB cannot be 
ruled out as co-administration of probenecid slightly increased the initial brain uptake of indomethacin from 
protein-free medium. Ketoprofen and indomethacin are able to permeate the CSF of children after intravenous 
administration. The CSF permeation of ketoprofen and indomethacin was limited after intravenous 
administration since only less than 1% of the total plasma drug concentration was found in the CSF. Whether 
this is sufficient to mediate any central antinociceptive effects in the lumbar space, or be involved in other 
central mechanisms of action remains to be clarified.  
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Protein Binding; Anti-Inflammatory Agents, Non-Steroidal/pharmacokinetics; Ibuprofen/pharmacokinetics; 
Ketoprofen/pharmacokinetics; Indomethacin/pharmacokinetics; Probenecid; Rats; Infant; Child, Preschool; 
Child; Clinical Trials as Topic 
 
ACKNOWLEDGEMENTS 
 
   The present study was carried out in the Department of Pharmaceutical Chemistry, 
University of Kuopio during the years 2002 - 2007. The study was financially supported by 
the Finnish Funding Agency for Technology and Innovation, The Academy of Finland, the 
Finnish Cultural Foundation (Elli Turunen Foundation), the Association of Finnish 
Pharmacies and The Finnish Pharmaceutical Society. 
   
   I gratefully acknowledge my supervisors for all their inputs. Docent Jouko Savolainen, my 
principal supervisor – thank you for introducing me to the world of CNS research and keeping 
your door always open for me. Thank you for teaching me so much about being a scientist. 
Professor Jarkko Rautio – thank you for all the guidance that you have given me during these 
years. In these final phases of my studies your support has been truly valuable. Professor 
Tomi Järvinen – thank you for taking me into your research group and providing me support 
whenever I needed it. As a whole, you have had a major influence on my career as a 
researcher.   
   
   I wish to acknowledge my co-authors for their contributions to this work. Marko Lehtonen 
M.Sc. is acknowledged for his expertise in analytical method development and validation, and 
Mikko Gynther M.Sc. is acknowledged for teaching me the in situ brain perfusion method, as 
well as for all the helpful scientific discussions. Anne Lecklin Ph.D. is acknowledged for 
introducing the cardiac perfusion technique to me. Marja Heikkinen MD, Merja Laisalmi 
MD, Elina Kumpulainen BM, Hannu Kokki MD, Ph.D. are gratefully acknowledged for 
conducting the clinical part of these studies and also for giving valuable feedback. Hanna 
Leena Louhisto M.Sc. and Ms. Terhi Salo are acknowledged for their contributions in the 
laboratory. I also wish to thank Ewen MacDonald Ph.D., Docent Jace Callaway and Karen 
White Ph.D. for refining the English of this thesis and the published papers. Vesa Kiviniemi 
Ph.Lic. is acknowledged for statistical advise and Marja-Leena Laitinen, Ph.D. for her help in 
GC-MS method development. 
    
   Professor Jukka Mönkkönen and Professor Jukka Gynther, the current and the former Deans 
of the Faculty of Pharmacy, and Professor Antti Poso, Professor Tomi Järvinen and Professor 
Seppo Lapinjoki, the current and the former heads of the Department of Pharmaceutical 
Chemistry are all gratefully acknowledged for creating and maintaining the excellent facilities 
and working environment. The faculty office personnel are acknowledged for their 
contribution to the paperwork and computer maintenance. I also wish to thank members of the 
Pharmaceutical and Medicinal Chemistry Group with whom I had the priviledge to work.  
Ms. Helly Rissanen and Ms. Anne Riekkinen, I am so glad that you were there keeping 
everything in place in the laboratory. Kirsi Luoto Ph.D., thank you for introducing me to 
quality assurance systems. Krista Laine Ph.D., thank you for your input to the CNS group. 
Fellow Ph D. students in the PMC group – thank you all for contributing to the great spirit in 
our research group.  
 
   I wish to express my sincere gratitude to the official reviewers of this work Pekka Suhonen 
Ph.D. and Elizabeth CM de Lange Ph.D. Thank you for accepting the invitation to be the 
official reviewers of my thesis and putting so much time and thought to the task. I found your 
comments extremely valuable. I also warmly thank Docent Jouni Sirviö for kindly accepting 
the invitation to be the opponent in the public examination of this thesis. 
 
   I wish to warmly thank Tarja Toropainen Ph.D., Laura Matilainen Ph.D. and Elina Turunen 
M.Sc. from the PMC group. You were wonderful colleagues - thank you for all the scientific 
and non-scientific discussions, laughs, support and most importantly, for your continuing 
friendship. I also wish to thank my dear workmates at the Centre for Drug Candidate 
Optimisation. Alison Gregg Ph.D., Karen White Ph.D, Maria Koltun Ph.D. and Tien Nguyen 
Ph.D. - you guys seem to always find the right words at the right time, thank you for all the 
encouragement and friendship which I have found so helpful when finalising my thesis here 
in Melbourne.  
 
   Finally, I want to warmly thank my family for their love and support; my parents Pirjo and 
Aarre, my brother Janne, my parents-in-law Eeva and Martti, and my sisters-in-law Katri and 
Kaisa, thank you for everything. I am so lucky to have such a superb family. Janne - thank 
you for being there. Not only have you been a loving husband providing me with heaps of 
support, the possibility to submerge myself into this thesis and times for relaxation and fun, 
you have also been the one to read the first versions of my manuscripts, to be the test 
audience for my presentations and to ponder any scientific question I had. With you by my 
side I feel everything is possible. 
 
 
Melbourne, Australia, April 2009 
 
 
Anne Mannila 
 
    
 
 
 
ABBREVIATIONS 
 
Aβ  Amyloid β  
AD  Alzheimer’s disease 
AMT  Absorptive-mediated transcytosis 
AUC   Area under the concentration - time curve 
BBB  Blood-brain barrier 
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BSA  Bovine serum albumin 
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CLin  Influx clearance 
CLout  Efflux clearance 
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CSF  Cerebrospinal fluid 
CNS  Central nervous system 
COX  Cyclooxygenase 
CVO  Circumventricular organ 
ECF  Extracellular fluid 
GC-MS  Gas chromatography - mass spectrometry 
HPLC  High performance liquid chromatography 
i.m.  Intramuscular 
i.p.  Intraperitoneal 
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ISF  Interstitial fluid 
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MRI   Magnetic resonance imaging 
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NSAID  Non-steroidal anti-inflammatory drug 
OAT  Organic anion transporter 
OATP  Organic anion transporting polypeptide  
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PET   Positron emission tomography 
P-gp  P-glycoprotein 
pKa  Negative logarithm of the ionization constant 
RMT  Receptor-mediated transport 
RP-HPLC  Reversed phase high performance liquid chromatography 
SD  Standard deviation 
SEM  Standard error of mean 
SPE  Solid phase extraction 
SPECT   Single photon computed tomography 
SS  Steady-state 
tmax  Time at which the maximum drug concentration is reached 
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1 INTRODUCTION 
   Advances in neurosciences and biotechnology have greatly expanded our knowledge about 
the physiological and pathological features of the central nervous system (CNS). When this 
knowledge is combined with advances in pharmaceutical sciences, then one would predict 
that this could lead to an increase in the number of drugs available for the treatment of CNS 
diseases. However, many CNS disorders still lack efficient drug therapy. CNS drug 
development must overcome some fundamental challenges, e.g. many novel agents that 
appear promising in vitro fail to evoke activity in vivo in preclinical studies. This is often due 
to the fact that these agents are not able to permeate into their site of action (i.e. the CNS), 
because they cannot pass across the barriers between the CNS and blood after systemic 
administration (Pardridge 2003). 
 
   The CNS is protected against internal, blood-borne damage that might either disturb its 
homeostasis or be toxic by the presence of the sophisticated structures called the blood-brain 
barrier (BBB) and the blood-cerebrospinal fluid barrier (BCSFB). These barriers act both as 
physical, metabolic and efflux barriers (Minn et al. 2000). The physical barrier is formed by 
the cells in the blood-CNS-barriers which prevent the entry of polar and high molecular 
weight molecules. The metabolic barrier results from the activity of a battery of enzyme 
systems present in the cells of blood-CNS-barriers. Finally, the various efflux protein systems 
which are able to transport compounds from the CNS to the systemic circulation create the 
efflux barrier.  
 
   The BBB and the BCSFB are extremely efficient at limiting and regulating the exchange of 
compounds between the CNS and blood. In general terms, there are four mechanisms by 
which a compound may access the CNS i.e. transcellular passive diffusion, carrier-mediated 
transport, receptor-mediated transcytosis and adsorptive-mediated transcytosis (Tsuji 2000). 
Usually small molecular weight compounds utilize passive diffusion or carrier-mediated 
transport mechanisms whereas large molecules such as proteins take advantage of receptor- or 
adsorptive-mediated mechanisms. If a drug is to pass the BBB or the BCSFB by passive 
diffusion, it must possess favourable physicochemical properties, such as adequate 
lipophilicity (Begley 2004). In contrast, the carrier- or receptor-mediated mechanisms require 
specific interactions between the drug and the transport protein, and are therefore limited only 
to drugs which closely resemble the endogenous substrate of the transport protein or receptor.        
 
   The blood-CNS barriers can be bypassed by delivering drugs directly into the brain or CSF 
e.g. via intraventricular, intraparenchymal, intrathecal and also by the nasal route (Begley 
2004).  However, the transvascular route, i.e. systemic administration of the drug followed by 
penetration through the BBB or BCSFB, remains the most straightforward way to deliver 
drugs to the CNS (Pardridge 2003). Therefore, there is an evident need for obtaining 
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knowledge about the BBB or BCSFB transport properties of compounds. Gaining such 
information will enable the development of efficient CNS drug delivery technologies which 
will hopefully lead to an increase in the number of drugs available for the treatment of CNS 
diseases. 
 
   Often novel CNS drugs are large molecular weight compounds such as proteins and genes 
which have obvious inherent permeation limitations, but also the CNS permeation of many 
widely used small molecular weight drugs may not be fully understood. For instance, the CNS 
distribution of non-steroidal anti-inflammatory drugs (NSAIDs) such as ibuprofen, 
indomethacin and ketoprofen is of interest because in addition to their well-known peripheral 
actions, they may also have important central actions. For example, some of their 
antinociceptive actions are believed to occur in the CNS (Daher and Tonussi 2003, Malmberg 
and Yaksh 1992, Ossipov et al. 2000). In order to act at the central level, a sufficient amount 
of a drug must gain access to the CNS. However, little is known about the CNS distribution of 
NSAIDs such as ibuprofen, indomethacin and ketoprofen. In children in particular, the 
information about the CNS distribution of these commonly used antinociceptive agents is 
extremely limited. In addition to being potential centrally acting antinociceptive agents, 
NSAIDs may have other beneficial central actions. Several epidemiological studies have 
claimed that long-term use of NSAIDs may reduce the risk or delay the onset of Alzheimer's 
disease (AD) (Szekely et al. 2004, Etminan et al. 2003, Vlad et al. 2008).  NSAIDs are weak 
acids and ionized at the pH of the systemic circulation and additionally, they are extensively 
bound to plasma protein albumin (Burke et al. 2006). These characteristics of NSAIDs may 
limit their CNS permeation, and therefore limit their use as centrally acting agents.      
 
   The aim of the present study was to evaluate the CNS disposition of NSAIDs ibuprofen, 
indomethacin and ketoprofen. The extent of CNS permeation was evaluated based on the ratio 
between the brain and the plasma concentration in rats or based on the ratio between the CSF 
and the plasma concentration in children.  
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2 REVIEW OF LITERATURE 
2.1 Central nervous system drug delivery 
2.1.1 Central nervous system 
   Basically, CNS is composed of the brain and the spinal cord. However, in terms of the 
tissue components, the brain volume can be subdivided into four compartments i.e. 
parenchyma (brain cells), parenchymal interstitial fluid (ISF), CSF and cerebral blood 
(Davson and Segal 1996). The cells of the brain include both nerve cells (neurons) and glial 
cells. The ISF is a flowing fluid providing an optimal microenvironment to bath the brain 
cells and it is mainly secreted at the cerebral capillary wall (Abbott 2004). The other fluid 
compartment, the CSF, surrounds the brain and the spinal cord. It is secreted from the blood 
by the choroid plexus, which is located in the lateral, 3rd and 4th ventricles. The CSF flows 
from the ventricles through the subarachnoid space into different parts of the brain and spinal 
cord. Ultimately, the CSF drains through arachnoid granulations into the dural sinuses and 
then to the venous system. The CSF maintains the medium for the CNS and acts both as an 
elimination pathway and a mechanical cushion for the brain and spinal cord (Rowland et al. 
1991). The cerebral vasculature density is high and it has been suggested that every neuron is 
perfused by its own blood vessel (Pardridge 2003). As a result, the transvascular route is a 
very efficient way to deliver compounds into the CNS. 
 
   There are several pathways for compound transfer between the different CNS compartments 
(Figure 2.1). The mixing between the ISF and the brain parenchyma is limited, as the bulk 
flow of the ISF is restricted to the white matter and the perivascular space of the brain (Abbott 
2004). The ISF and the CSF are in intimate contact with each other and share a similar 
composition, e.g. a low protein concentration (Davson and Segal 1996). Together the ISF and 
the CSF make up the extracellular fluid (ECF) of the CNS. The transfer of solutes between 
the ISF and the CSF has not been exhaustively investigated. From the CNS drug delivery 
point of view, it appears that differences in drug concentrations between ISF and CSF are 
common (De Lange and Danhof 2002, Shen et al. 2004).  
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Figure 2.1. Simplified model of the CNS compartments (modified from de Lange and Danhof 
2002). 
 
   Furthermore, the ISF and the CSF have a role in compound clearance from the CNS. The 
ISF is a flowing liquid and its clearance occurs primarily by bulk flow along the perivascular 
space to the CSF (Abbott 2004). Therefore, once a compound is present in the ISF, it can 
leave the CNS not only by passing through the BBB back to cerebral blood vessels but also 
through passage into the CSF. The turnover rate of the CSF is faster than that of the ISF 
(Davson and Segal 1996), and it is recognised that due to its continuous turnover, CSF can act 
as a sink for brain tissue. Continuous CSF turnover is one of the factors (others including 
metabolism and active efflux mechanisms in the CNS) that may explain why many 
compounds have a steady-state ISF or CSF to unbound plasma concentration ratio of less than 
unity (Table 2.1). The impact of CSF turnover is most pronounced with compounds that 
penetrate the CNS very slowly, because in these cases the clearance from the CNS by CSF 
turnover is rapid relative to the influx of the compound across the blood-CNS barriers 
(Rowland and Tozer 1995, Davson and Segal 1996).  
 
BBB 
Cerebral blood 
BCSFB 
Brain 
ventricular 
CSF 
 
 
 
Lumbar spinal 
CSF 
Brain parenchyma 
(intracellular compartments 
of the brain) 
  ISF 
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Table 2.1. Examples of compounds that have low CSF or ISF to unbound plasma 
concentration ratios.  
Compound Dosing CSF:plasma 
(Method of collecting 
CSF) 
ISF:plasma Ref. 
Salicylic acid I.v. infusion in dogs,  
CSF samples collected 
3 hours after reaching 
SS in plasma 
 
Approximately 0.6 
(Cisternal catheter) 
- (Brodie et al. 
1960) 
Sulfaguanidine I.v. infusion in dogs,  
CSF samples collected 
3 hours after reaching 
SS in plasma 
 
Approximately 0.4 
(Cisternal catheter) 
- (Brodie et al. 
1960) 
Probenecid SS i.v. infusion in rats 0.629 
(Cisternal puncture) 
0.199 
(Hippocampal 
microdialysis) 
 
(Deguchi et al. 
1997) 
SDZ EAA 494 
(NMDA receptor 
antagonist) 
 
I.v. injection in rats, 
comparison of AUCs 
 
0.17 
(Cisternal catheter) 
0.11 
(Frontal cortex 
microdialysis) 
(Amsterdam 
and  Lemaire 
1997)  
EAB 515 
(NMDA receptor 
antagonist) 
 
SS i.v. infusion in rats  0.18 
(Lateral ventricle 
microdialysis) 
0.08 
Frontal cortex 
microdialysis 
(Malhotra et 
al. 1994)  
Stavudine SS i.v. infusion in rats 0.50 
(Lateral ventricle 
microdialysis) 
 
0.34 
(Frontal cortex 
microdialysis) 
(Yang et al. 
1997) 
Ofloxacin 
 
 
 
SS i.v. infusion in rats 
 
0.234 
(Cisternal puncture) 
0.118 
(Transcranial 
microdialysis) 
(Ooie et al. 
1997)  
Fleroxacin 
 
 
 
SS i.v. infusion in rats 
 
0.420 
(Cisternal puncture) 
0.147 
(Transcranial 
microdialysis) 
(Ooie et al. 
1997) 
Perfloxacin 
 
 
 
SS i.v. infusion in rats 
 
0.369 
(Cisternal puncture) 
0.147 
(Transcranial 
microdialysis) 
(Ooie et al. 
1997) 
Norfloxacin 
 
 
 
SS i.v. infusion in rats 
 
0.033 
(Cisternal puncture) 
0.034 
(Transcranial 
microdialysis) 
(Ooie et al. 
1997) 
Baclofen 
 
 
 
I.v. injection in rats 
(Pseudo-SS) 
 
0.0277 
(Cisternal puncture) 
0.0346 
(Hippocampal 
microdialysis) 
(Deguchi et al. 
1995)  
Ganciclovir SS i.v. infusion in rats 0.067 
(Cisternal puncture) 
0.073 
(Frontal cortex 
microdialysis) 
(Liu et al. 
2008) 
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The interaction of the blood compartment with the other compartments is strictly regulated by 
complex CNS barrier systems. The BBB between cerebral blood and ISF is formed by the 
cerebrovascular endothelial cells whereas the BCSFB between blood and ventricular and 
subarachnoid CSF is formed by the epithelial cells in the choroid plexus and arachnoid 
membrane (Johanson et al. 2005). These barriers are crucial in many respects; the CNS can 
maintain a tight ionic homeostasis, restrict and regulate the turnover of both small and large 
molecules, separate peripheral and central neurotransmitter pools and maintain immune 
surveillance (Abbott 2004). The BBB and the BCSFB are crucial barriers to be overcome in 
successful CNS drug therapy since the systemic route is still considered the most efficient 
way to deliver drugs into the CNS (Pardridge 2003). Therefore, drugs that cannot pass the 
BBB or the BCSFB sufficiently cannot be used to treat CNS disorders. 
2.1.1.1 The blood-brain barrier 
   The blood-CNS barriers can be envisaged as a three-part barrier system (Minn et al. 2000). 
The physical barrier is formed by the cells in the blood-CNS-barriers and this prevents the 
entry of polar and high molecular weight molecules into the CNS. The metabolic barrier 
results from the activity of a battery of enzyme systems present in the cells of the blood-CNS-
barriers. In addition, various efflux protein systems which are able to remove compounds 
from the CNS to the systemic circulation create an efflux barrier. The physical, metabolic and 
efflux barriers will be discussed in more detail below. 
 
The physical barrier 
   The basis of the physical barrier at the level of the BBB is formed by the endothelial cells in 
the brain capillaries. They are joined together by tight junctions, thus preventing the 
paracellular transport of compounds. The tight junctions of the brain endothelium are more 
complex than those present in the peripheral tissue endothelium (Wolburg and Lippoldt 
2002). The degree of tightness of these junctions, as measured by transendothelial electrical 
resistance higher than 1000 Ωcm2, resembles that found in barrier epithelial cells (Schulze 
1996). For comparison, the transendothelial electrical resistance is only about 2-20 Ωcm2 in 
peripheral capillaries (Abbott et al. 2006). An efficient barrier against paracellular transport is 
formed not only because of the existence of tight junctions, but also because endothelial cells 
at the BBB lack fenestrae and because pinocytosis rarely occurs (Schulze 1996).  
 
   In addition to the capillary endothelial cells, the BBB contains also pericytes, astrocytes, 
microglia and nerve endings which contribute to the physical barrier (Abbott et al. 2006). For 
instance, astrocytes form an extra layer around the endothelial cells thus forcing substances to 
cross several cell membranes in order to pass through the BBB (Figure 2.2). 
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Figure 2.2. Structure and different transport mechanisms present at the BBB.  
 
The metabolic barrier 
   The metabolic barrier of the BBB consists of various metabolic enzymes. As substances 
pass the BBB by the transcellular route, they are inevitably exposed to enzymes within the 
cells at the BBB (Ghersi-Egea et al. 1995). The BBB expresses both phase I and phase II 
enzymes (Minn et al. 1991). In addition, ATP-dependent efflux transport mechanisms can be 
classified as a type of phase III enzymatic system, as they are able to remove polar 
metabolites from the CNS. Some enzymes, such as γ-glutamyl transferase, alkaline 
phosphatase, adenosine deaminase and purine-nucleoside phosphorylase have higher 
activities at the BBB than in the brain tissue (Johnson and Anderson 1996).  This provides 
further evidence that they possess a protective function at the BBB. However, metabolic 
enzymes have a somewhat contradictory role in the BBB since in addition to their protective 
functions, their activity can also produce reactive metabolites or oxygen species which may 
endanger the CNS, e.g. by accelerating neurodegeneration (Minn et al. 2000). From a drug 
delivery point of view, metabolism at the BBB or in the CNS can result in inactivation of 
pharmacologically active molecules which will impede efficient drug therapy. On the other 
hand, enzymes located at the BBB can be utilized to achieve site-specific drug delivery to the 
CNS via a prodrug approach where the probability of success increases if the prodrug 
bioconversion takes place selectively in the CNS (Anderson et al. 1991). 
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The efflux barrier 
   P-glycoprotein (P-gp) is probably the most well-known efflux protein which is able to 
prevent compounds from entering the CNS. It was originally characterized as a protein able to 
confer multidrug resistance to cancer cells and only later as having a role in CNS distribution 
and intestinal absorption of drugs (Lin and Yamazaki 2003, Schinkel 1999). P-gp is an ATP-
dependent transport protein which is located at the luminal (blood-side) membrane of brain 
capillary endothelial cells (Schinkel 1999). P-gp is able to recognise and transport a great 
number of structurally diverse compounds; its substrates include antineoplastic drugs such as 
doxorubicin, vinblastine and paclitaxel, HIV protease inhibitors nelfinavir, indinavir and 
saquinavir and the immunosuppressant, cyclosporin A (Schinkel 1999). In vivo experiments 
in P-gp knockout mice and other animal models have established the role played by P-gp in 
the BBB. For instance, after a single bolus injection, significantly higher brain levels as well 
as accumulation in the brain tissue of a P-gp substrate digoxin (and the pharmacologically 
active metabolites of digoxin) were observed in P-gp knockout mice compared to wild-type 
mice (Mayer et al. 1996). Also the plasma levels of digoxin (and its pharmacologically active 
metabolites) were higher in the P-gp knockout mice indicating the effect of P-gp on the 
systemic pharmacokinetics of digoxin. The increase in the plasma levels of digoxin explains 
partly the increased brain levels of digoxin. Other examples showing the functional role of P-
gp in the BBB include the study by Wang et al. (1995), where increased brain delivery of a P-
gp substrate rhodamine-123 was observed in the presence of a P-gp inhibitor cyclosporine A, 
the study by de Lange et al. (1998) where increased brain delivery of rhodamine-123 was 
observed in P-gp knockout mice compared to wild-type mice, as had also been found by Xie 
et al. (1999) for morphine, another known P-gp substrate. The clinical relevance of P-gp has 
been demonstrated, for instance in the case of the antidiarrheal compound, loperamide. 
Loperamide is a potent opiate which does not normally enter the CNS because it is a substrate 
for P-gp. However, when administered with quinidine, a P-gp inhibitor, loperamide produces 
respiratory depression indicative of enhanced CNS entry. Thus, potentially dangerous CNS 
effects can appear due to increased CNS penetration after P-gp inhibition (Sadeque et al. 
2000). 
 
   P-gp is member of the ABC transporter family. Other members of the ABC transporter 
family that have been suggested to have a role at the BBB include isoforms of multidrug 
resistance-associated proteins (MRPs) and breast cancer resistant protein (BCRP) (Wijnholds 
et al. 2000, Leggas et al. 2004, Cisternino et al. 2004). MRP1 and 5, and the BCRP have been 
suggested to be localised on the luminal side of brain microvessel endothelial cells, whereas 
MRP4 has been proposed to be situated on both the luminal and abluminal (brain) sides 
(Zhang et al. 2004, Cisternino et al. 2004). The substrates for P-gp, MRPs and the BCRP 
overlap to some extent - MRPs can be characterised as a group of transporters for organic 
anions, glutathione, or glucuronide-conjugated compounds (Jedlitschky et al. 1996), and the 
BCRP has been reported to transport mitoxantrone, prazosin, anthracyclines and some 
camphoteric derivatives (Cisternino et al. 2004).  
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   Members of the solute carrier families SLC21 and SLC22, i.e. organic anion transporting 
polypeptides (OATPs), organic anion transporters (OATs) and organic cation/carnitine 
transporters (OCTNs) are believed to be involved in the transport of a wide range of 
substrates, such as bile salts, steroid hormones and their conjugates, thyroid hormones,  
anionic peptides, eicosanoids, cyclic nucleotides, endogenous amines, uric acid, cardiac 
glycosides, antibiotics, NSAIDs, diuretics, antineoplastic drugs, uricosuric agents, 
tetraethylammonium and carnitine (Hagenbuch et al. 2004, Koepsell and Endou 2004). 
OATPs, OATs and OCTNs are expressed in many different tissues, and there is evidence for 
their central role in drug absorption and excretion particularly in intestine, liver and kidney. 
They are also involved in the efflux of various compounds, particularly organic anions, at the 
BBB (Hagenbuch et al. 2004, Koepsell and Endou 2004, Kusuhara and Sugiyama 2005). 
There are many members of the OATP family, but at least rat Oatp1a4, Oatp1a5 and Oatp1c1 
are expressed in the brain capillaries. Oatp1a4 and Oatp1c1 are thought to be localised both 
on the luminal and abluminal membranes of the brain capillaries and to be involved in both 
efflux and uptake of compounds (Kusuhara and Sugiyama 2005). For example, it is suggested 
that the transport of thyroxine both from the circulating blood to the brain and from brain to 
blood is mediated by Oatp1c1 (Sugiyama et al. 2003). It is also believed that rat Oat3 has a 
role at the BBB (Kusuhara et al. 1999) since it appears to be localised on the abluminal 
membrane of the brain capillaries and has been shown to be involved in the efflux transport of 
indoxyl sulphate and thiopurine nucleobase analogs (Mori et al. 2004, Kikuchi et al. 2003, 
Ohtsuki et al. 2002). From the solute carrier families also monocarboxylic acid transporters 
(MCTs) may have a role as an efflux mechanism at the BBB, as the CNS distribution of 
probenecid, salicylate and neotrofin are suggested to be mediated by the MCT system 
(Deguchi et al. 1997, Yan and Taylor 2002). 
2.1.1.2 The blood-cerebrospinal fluid barrier 
   The BCSFB exists at the level of the choroid plexus and the arachnoid membrane (Johanson 
et al. 2005). Traditionally, the choroid plexus has been perceived as having a larger role in 
compound transfer between blood and the CSF than the arachnoid membrane, and it is thus 
discussed in more detail. The BCSFB has characteristic structural and functional properties 
that distinguish it from the BBB. In contrast to the endothelial cells in brain capillaries, the 
capillaries in the choroid plexus lack tight junctions and are therefore freely permeable. The 
barrier is formed by the epithelial cells of the choroid plexus which face the CSF (Rowland et 
al. 1991). In the choroid plexus the activity of several metabolic enzymes is relatively high. 
For example, in the rat choroid plexus the activities of glutathione peroxidase and several 
cytochrome P450 isoenzymes are high, and the activities of UDP-glucuronosyltransferase and 
epoxide hydrolase are very high, being at the same level as those in the liver when expressed 
on a per mg protein basis (Ghersi-Egea et al. 1995). Furthermore, at the level of the BCSFB, 
active transport mechanisms are abundant (Kusuhara and Sugiyama 2004). Although the same 
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efflux transporters can be found in the choroid plexus and at the BBB (Figure 2.3), functional 
differences exist between the BCSFB and the BBB (de Lange 2004). For instance, it is 
believed that the efflux of penicillin occurs specifically at the choroid plexus (Ogawa et al. 
1994). The role of P-gp at the BCSFB is presently unclear (Kusuhara and Sugiyama 2004). 
The best-characterised MRP isoform MRP1 is believed to have a role in the efflux of 
compounds across BCSFB but not to be involved in efflux across the BBB (Wijnholds et al. 
2000), although not all researchers subscribe to its lack of a role in the BBB (Zhang et al. 
2004).  
 
 
Figure 2.3. Simplified diagram of the efflux barrier at the BBB (A) and at the BCSFB (B). 
BCRP = breast cancer resistant protein, Mrp = multidrug resistant-associated protein, Oat = 
organic anion transporter, oatp = organic anion transporting polypeptide, oct = organic cation 
transporter, PEPT = peptide transporter, P-gp = P-glycoprotein, RST = renal specific 
transporter (Kusuhara and Sugiyama 2004, Kusuhara and Sugiyama 2005). 
 
   It has been traditionally believed that the role of the BCSFB in drug delivery to the CNS is 
not as significant as the role of the BBB. This belief is largely based on the smaller surface 
area of the BCSFB. However, this view has been challenged e.g. the vascular perfusion of the 
choroid plexus is approximately eight times higher compared to that of the total brain, and the 
choroid plexus also has larger surface area than thought previously - the estimated total apical 
surface area of the choroid plexus (75 cm2 for 30-day-old rats) is very similar to the estimate 
for the surface area of the cerebral capillaries (155 cm2 for 30-day-old rats) (Keep and Jones 
1990, Faraci et al. 1994, Johanson et al. 2005). Furthermore, it is known that the vitamin C 
supply to the CNS occurs solely via the choroid plexus and not across the BBB (Rice 2000) 
emphasizing the importance of the BCSFB in the CNS delivery of some compounds. 
Therefore, recently it has been claimed that not only the BBB, but also the BCSFB seems to 
be exploitable for drug delivery to the brain (Johanson et al. 2005).  
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2.1.1.3 Circumventricular organs 
   In the CNS, the so-called circumventricular organs (CVOs) are a family of organs that lack 
the typical features of the BBB, such as the endothelial tight junctions. Therefore, their 
capillaries are generally highly permeable to blood-borne compounds (Rowland et al. 1991). 
The choroid plexus is one of the CVOs. The other CVOs are located on the walls of the 3rd 
and 4th ventricles and include the pineal gland, subfornical organ, subcommissural organ, 
organum vasculosum of the laminar terminalis, the area postrema, median eminence and 
neural lobe of the hypophysis. The CVOs possess neuroendocrine-type functions. They 
receive signals from and secrete products into both plasma and CSF. In other words, at the 
level of the CVOs, the brain can interact rapidly with blood-borne solutes (Begley 2004). 
Further diffusion of these blood-borne solutes within the brain is limited by the surrounding 
ependyma layer where adjacent cells form tight junctions (Rowland et al. 1991). In addition, 
metabolic enzymes are abundant in the CVOs, forming an enzymatic barrier between blood 
and the rest of the CNS (Ghersi-Egea et al. 1995). 
2.1.2 Factors affecting drug permeation into the central nervous system 
   CNS permeation of drugs is an important issue in modern drug development because many 
new agents developed for CNS disorders cannot permeate into the CNS and therefore, cannot 
reach their site of action. The reason why the CNS permeation of drugs is so crucial is that the 
transvascular route remains the most desired way to deliver drugs to the CNS (Pardridge 
2003). The other routes, i.e. intraventricular, intraparenchymal, intrathecal and nasal route 
may be advantageous occasionally but are unlikely to displace the transvascular route as the 
most common route of drug administration to reach the CNS (Huynh et al. 2006, Begley 
2004).   
 
   Basically, there are four mechanisms that a compound may use in order to gain access to the 
CNS (Tsuji 2000), i.e. transcellular passive diffusion, carrier-mediated transport, receptor-
mediated transcytosis and adsorptive-mediated transcytosis (Figure 2.2). Usually small 
molecular weight compounds enter via passive diffusion or carrier-mediated transport 
mechanisms whereas large molecules such as proteins utilize receptor- or adsorptive-mediated 
mechanisms. The ability of the drug to pass the BBB or the BCSFB by passive diffusion 
depends greatly on the physicochemical properties of the drug whereas the carrier- or 
receptor-mediated mechanisms require specific interactions between the drug and the 
transport protein or receptor.        
2.1.2.1 Physicochemical properties of the drug 
   There is a well-established relationship between increasing lipid solubility and increasing 
BBB penetration with regard to passive transport (Levin 1980). The lipophilicity of a 
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molecule can be evaluated by determining its logarithmic octanol-water partition coefficient 
(log Poct). Historically, based on biological activity data, a log P value of near 2 has been 
believed to be optimal for brain uptake.  In a recent study with a set of CNS drugs with a wide 
range of calculated log Poct values (from -0.2 to 6.1) a nonlinear relationship was observed 
between lipophilicity and in situ brain permeability values determined using an in situ brain 
perfusion method in rats (Summerfield et al. 2007). When calculated log Poct was less than 2-
3, a linear relationship was observed, but with calculated log Poct values higher than 
approximately 3, the increase in the log Poct no longer resulted in an increase in the in situ 
brain permeability values and a plateau effect was observed .  
 
   Ionization (i.e. charge) of a compound affects its ability to enter the CNS (Brodie et al. 
1960). It is generally believed that charged molecules cannot penetrate through the 
BBB/BCSFB. This would mean that the CNS permeation of drugs that are partially ionized at 
the pH of the circulation will be determined by the unionized fraction of the drug. In addition, 
certain molecular characteristics such as polarity, polar surface area, Lewis bond strength, 
potential for hydrogen bond formation, molecular weight or volume, can influence the  ability 
of a compound to cross the BBB/BCSFB (Begley 2004). These characteristics can be used to 
predict brain uptake of drugs and it has been suggested that descriptors such as hydrogen 
bond descriptors should be used instead of commonly used log P values in order to obtain 
better correlations with BBB/BCSFB permeability (Abraham and Platts 2000). 
 
   Generally, molecules that are both lipid soluble and have molecular weight less than a 
threshold of 400-600 Da can readily penetrate through the BBB/BCSFB, the extent of 
penetration being in proportion to their lipid solubility (Pardridge 1995). Molecules that do 
not exhibit favorable physicochemical properties may still penetrate into the CNS if they can 
take advantage of carrier-mediated transport mechanisms at the BBB/BCSFB (see chapter 
2.1.2.3). Conversively, the CNS penetration of a compound may be far less than would be 
predicted based on its lipid solubility, for example if it is a substrate for the efflux 
mechanisms present at the BBB and the BCSFB, which have been discussed earlier in context 
of the efflux barrier (chapter 2.1.1.1).  
2.1.2.2 Pharmacokinetics of the drug 
   Pharmacokinetics in the periphery affects the CNS permeation of drugs by affecting the 
amount of a drug available for uptake. Several factors such as peripheral distribution volume, 
extent of metabolism and plasma protein binding greatly affect the CNS availability of a drug 
after its systemic administration (Pardridge 1995).  
 
   Traditionally it has been believed that only the fraction of the drug that is not bound to 
plasma proteins is able to pass through biological membranes including the BBB and the 
BCSFB (the "free drug rule") (Rowland and Tozer 1995). Thus, the CNS delivery of drugs 
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that are partially bound to plasma proteins is greatly influenced by plasma protein binding. It 
is appreciated that both the equilibrium state of protein-drug binding and the rate of 
dissociation of a drug from the protein affect the drug transfer across the blood-CNS barriers 
(Fenstermacher 1989). This means that if the rate of dissociation is slow relative to the 
capillary transit time of plasma proteins, drugs that are bound to plasma proteins may not be 
available for transfer across the blood-CNS barriers whereas protein-bound drugs whose rate 
of dissociation is rapid may become free during their passage through the cerebral capillaries 
and consequently become available for transfer. 
 
   Some discrepancy exists regarding the "free drug rule" in the sense that it has been 
suggested that the unbound fraction may not explain the CNS uptake in vivo and also the 
protein-bound fraction may still be available for transport across the BBB to some extent 
(Tanaka and Mizojiri 1999, Jolliet et al. 1997). The proposed explanation to the exception for 
the free drug rule is that a conformational change occurring in albumin when it enters brain 
capillaries could lead to enhanced dissociation of the drug from protein (Tanaka and Mizojiri 
1999, Pardridge 1995). These observations have been demonstrated using the brain uptake 
index and in situ brain perfusion methods. However, in a steady-state condition after 
intravenous administration (Dubey et al. 1989) or by using an in situ brain perfusion method 
with a modified Kety-Crone-Renkin (parallel tube) model (Mandula et al. 2006) no 
enhancement in the dissociation of the drug from protein was observed.  
 
   Ideally, at steady-state, the unbound drug concentration in the brain or CSF and blood 
should be identical. In other words, the clearances into and out of the brain or CSF are 
equivalent. However, this kind of equilibrium may never be reached if the efflux clearance 
(CLout) exceeds the influx clearance (CLin). Factors that influence the CLout include active 
efflux mechanisms, metabolism in the CNS and the continuous CSF turnover (Hammarlund-
Udenaes 2000).  
2.1.2.3 Transport mechanisms at the blood-central nervous system interfaces 
   The BBB and the BCSFB express various influx transporter mechanisms. These 
transporters enable the CNS delivery of compounds which are fundamental to the normal 
functions of the brain but are restricted from CNS entry by passive diffusion due to their polar 
nature. Transport systems, which are shown to act as influx transporters at the BBB or at the 
BCSFB, include transporters for glucose, amino acids, monocarboxylic acids, organic cations, 
nucleosides, peptides and vitamin C (Tamai and Tsuji 2000). Some of the transporters at the 
blood-CNS barriers can be expressed in both sides of the barrier, and some of them act only 
as influx or as efflux transporters. Therefore, unambiguous classification to influx and efflux 
transporters is not appropriate, and some of the efflux transporters discussed in chapter 2.1.1.1 
may act also as influx transporters.   
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   Endogenous transport mechanisms can have relevance in the CNS delivery of drugs. A 
classical example of a drug which is delivered to the CNS via carrier-mediated transport is 
levodopa. In the body, including the brain tissue, levodopa is decarboxylated to the active 
compound dopamine but only levodopa is a substrate for the large neutral amino acid 
transporter (LAT1) and is thus able to reach the brain, the site of action (Tamai and Tsuji 
2000). Many drugs have been suggested to enter into the CNS via carrier-mediated transport 
mechanisms, and undoubtedly, in the future more and more drugs will be shown to be 
transported across the BBB or BCSFB via some specific transport protein (Dobson and Kell 
2008). In addition to levodopa, examples of drugs that are delivered into the CNS via carrier-
mediated transport include the anticancer agent melphalan and particularly its lipophilic 
analogue DL-NAM via LAT1 (Takada et al. 1992), the anticonvulsant agent, valproic acid via 
the transporter for medium-chain fatty acids (Adkison and Shen 1996), active forms of HMG-
CoA reductase inhibitors simvastatin and lovastatin via the transporter for monocarboxylic 
acids (Tsuji et al. 1993), and the H1-antagonist mepyramine via the transporter for cations 
(Yamazaki et al. 1994). 
 
   The BBB transport of large molecules, such as proteins, is dependent on specific receptors 
present at the BBB. For instance, the CNS delivery of iron and insulin occurs via receptor-
mediated transport (RMT) by transferrin and insulin receptors (Tsuji 2000). These receptors 
may be useful when delivering large molecular-weight therapeutic agents such as proteins or 
genes into the CNS (Pardridge 2002). Another transport mechanism for large molecules 
across the BBB is the absorptive-mediated transcytosis (AMT) which is less specific than the 
receptor-mediated transcytosis. AMT is based on electrochemical interactions between 
negatively the charged cell membrane and a positively charged moiety of the molecule (Tsuji 
2000). While there are reasonably promising data available about the brain delivery of large 
molecular weight compounds using the RMT mechanism in animal models, the clinical 
significance and the usefulness of RMT (and AMT) to target CNS delivery is yet to be seen as 
there are several issues to be resolved before these techiques can be successfully and safely 
transferred to humans (de Boer and Gaillard 2007).   
2.1.2.4 General view about drug delivery into the central nervous system 
   One of the factors affecting the CNS permeation of compounds is the cerebral blood flow. 
The cerebral blood flow and the capillary surface area may differ in different brain regions, 
and therefore, it can be presumed that this could lead to regional differences in brain uptake 
and disposition of drugs. A change in the blood flow is likely to be particularly relevant for 
those drugs whose brain uptake is fast and limited by the blood flow. The capillary surface 
area i.e. the number of perfused capillaries may, at least in theory, affect the CNS permeation 
of both highly and poorly permeable drugs (de Lange and Danhof 2002).  
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   Individual differences in humans may also have an impact on the CNS delivery of drugs. 
For instance, several diseases, such as stroke, brain tumours, infectious and inflammatory 
processes, Alzheimer's disease, Parkinson's disease, multiple sclerosis, HIV, and epilepsy may 
disrupt the intactness of the BBB (Abbott et al. 2006). Even peripheral inflammation stimuli 
have been shown to produce an increase in the BBB permeability (Huber et al. 2001). 
However, the consequences of this disease-related BBB disruption in CNS delivery of drugs 
remains to be clarified (de Lange and Danhof 2002). In addition, it can be hypothesized that 
individual variability in the expression of transport proteins at the blood-CNS barriers could 
have a role in the CNS delivery of drugs which are substrates for transport proteins. Figure 
2.4 shows some factors affecting the CNS transport of drugs. 
 
 
Figure 2.4. Factors affecting the rate and extent of CNS transport of drugs.  
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   It has to be remembered that from the CNS drug delivery view in general, both the rate of 
transport across the blood-CNS barriers and the extent of the CNS distribution are of 
importance. Furthermore, they should be understood as two separate processes which may be 
governed by different factors (Hammarlund-Udenaes 2000). For instance, a slow rate of 
transport across the blood-CNS barriers does not necessarily lead to a low level of drug in the 
CNS, and vice versa. The rate of transport is influenced largely by the physicochemical 
characteristics, and further, the permeation properties of the drug. For highly permeable 
drugs, the cerebral blood flow may become the rate-limiting factor. The influx rate of drugs is 
also affected by the efflux mechanisms at the BBB or BCSFB. In a recent study by Liu et al. 
(2005), it was suggested that also brain tissue binding has a role in the rate of CNS entry. 
When the rate was evaluated by the time to reach brain equilibrium, rapid CNS entry requires 
both high BBB permeability and low brain tissue binding. The extent of CNS distribution is 
determined by the CLin and CLout of a drug (Hammarlund-Udenaes 2000). Factors that 
influence the ratio between CLin and CLout include active influx or efflux mechanisms, 
metabolism in the CNS and the continuous CSF turnover. In addition, among lipophilic 
compounds, brain tissue binding has an effect on the uptake across the BBB as brain tissue 
binding may help to maintain a diffusion gradient across the BBB (Summerfield et al. 2007). 
As for total brain drug concentration as well as total brain to total plasma concentration ratio, 
drug binding in both plasma and in brain tissue has a crucial role (Liu et al. 2005, 
Summerfield et al. 2006).  
 
   Finally, as discussed in chapter 2.1.1., the CNS consists of various compartments and there 
are several pathways for compound transfer between the different compartments. The drug 
concentration can vary in different parts of the CNS and for instance nonspecific binding in 
the brain parenchyma as well as binding to specific receptors can affect the drug 
concentration in the CNS. Once present in the CNS, the drug is distributed into the 
extracellular and intracellular compartments. Extracellular brain concentrations are dependent 
on the intracellular distribution of a drug and it is drug-specific whether the extracellular or 
the intracellular drug concentration is more relevant (de Lange and Danhof 2002). 
2.1.3 Methods for improving central nervous system drug delivery 
   Many methods have been described in the literature for improving the CNS delivery of 
drugs that lack satisfactory BBB or BCSFB penetration properties. These methods include 
direct administration of a drug to its site of action through intracerebral or spinal injection or 
infusion, delivery via the olfactory route, transient modulation of the BBB with hypertonic 
solutions, with vasoactive agents or with ultrasound and electromagnetic radiation, cell-
penetrating peptide vectors and liposomes and nanoparticles (Begley 2004). All of the 
existing methods have their own benefits and drawbacks. Many of them have already been 
used successfully to improve the CNS delivery of a drug, as is the case in treating human 
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brain tumours.  In the present literature review, two methods for improving the CNS of 
therapeutics are described in more detail – lipidization of the drug as one of the traditional, 
chemical based approaches, and influencing the endogenous transport systems at the blood-
CNS barriers since this technique has been partially applied in the experimental studies.  
2.1.3.1 Lipidization of the drug 
   Optimization of the physicochemical properties of the drug molecule is a convenient way to 
improve its CNS delivery, since the blood-CNS barriers allow compounds to enter the CNS 
via passive diffusion only through the transcellular route. Enhancement of the CNS delivery 
has been achieved in several ways, e.g. by designing a lipid soluble analog of the drug, by 
using brain-targeting chemical delivery systems (Bodor and Buchwald 2002) or by increasing 
temporarily the lipophilicity of the drug molecule by the prodrug approach (Anderson 1996, 
Greig 1989). For instance, as a strategy to improve the CNS delivery of NSAIDs, a 
triglyceride prodrug of ketoprofen has been designed and evaluated in various animal models 
(Deguchi et al. 2000). It was discovered that following the administration of the triglyceride 
prodrug the AUC(brain) value of ketoprofen was increased when compared to administration of 
ketoprofen itself, and also that the brain uptake of the prodrug across the BBB was higher 
than that of  ketoprofen. These results suggested that the brain delivery of ketoprofen could be 
improved via this prodrug approach. The prodrug approach has been used also in attempts to 
improve the CNS delivery of an anticancer agent chlorambucil (Greig et al. 1990). A series of 
chlorambucil esters was prepared and the chlorambucil-tertiary butyl ester displayed an 
increased brain delivery compared to chlorambucil, and as a result, the brain to plasma 
concentration integral ratio of total active compounds derived from the prodrug was 35-fold  
greater than that derived from chlorambucil administration. However, of the total active 
compounds monitored in the brain, the chlorambucil-tertiary butyl ester itself (which has 
some alkylating activity) comprised the majority. This indicates that the ester prodrug 
exhibited slow cleavage rate in the brain tissue, and illustrates the challenges related to the 
prodrug approach – in order to enhance the CNS delivery, the prodrug needs to have optimal 
bioconversion rates both in the systemic circulation and in the CNS. Too rapid bioconversion 
rate in the systemic circulation may result in complete conversion of the prodrug to the parent 
compound before sufficient prodrug reaches the CNS, whereas too slow bioconversion rate in 
the CNS may mean that the parent compound is released too slowly compared to the rate at 
which the parent compound (or the prodrug) is cleared fron the CNS by passive diffusion 
back to the systemic circulation, CSF bulk flow or other clearance mechanisms (Anderson 
1996).  
 
   Unfortunately, increase in the lipophilicity of a drug - either by designing a more lipophilic 
analog or by a prodrug approach - may lead not only to improved BBB permeation but also to 
altered peripheral pharmacokinetics, e.g. improved permeation to peripheral organs, increased 
plasma protein binding and elimination. These undesirable effects on peripheral 
pharmacokinetics can decrease the plasma concentrations of the drug, and ultimately, this 
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may offset the positive effect of increased BBB permeability and the overall CNS availability 
may not be increased (Pardridge 2003). In addition, an increase in the lipophilicity can lead to 
an increase in the affinity for the efflux transporters at the BBB (Leisen et al. 2003) as well as 
to an increase in the non-specific binding in the brain tissue, all of which can lead to 
decreased efficacy (Summerfield et al. 2006, Summerfield et al. 2007).    
2.1.3.2 Influencing the endogenous transport systems 
   Endogenous transport mechanisms can have relevance in the CNS delivery of drugs because 
they can be utilized in the CNS uptake of drugs. On the other hand, inhibition of efflux 
proteins may enhance the CNS uptake of drugs whose permeation into the CNS is limited by 
efflux mechanisms.   
 
   One way to utilize the endogenous influx transporters at the blood-CNS barriers is to design 
a drug which closely resembles the endogenous substrate of the transport protein and is thus 
recognized and transported into the CNS.  A classical example of a drug which is delivered to 
the CNS via carrier-mediated transport is the LAT1 substrate, levodopa (Tamai and Tsuji 
2000). The prodrug approach can also be applied in order to utilize carrier-mediated transport 
across the blood-CNS barriers. There are some prodrugs designed to target various membrane 
transporters at blood-CNS barriers. For instance, there is an amino acid prodrug of a glycine-
NMDA receptor antagonist 7-chlorokynurenic acid which has been shown to be transported 
across the BBB by LAT1 (Hokari et al. 1996). Recently, it was reported that the amino acid 
prodrug of ketoprofen could also be transported across the BBB via LAT1, evidence that 
conjugation of a drug and a LAT1-substrate could promote carrier-mediated drug delivery to 
the brain (Gynther et al. 2008). In addition, in a prodrug approach where 7-chlorokynurenic 
acid was conjugated with D-glucose, it was suggested that the prodrug could be transported 
across the BBB via the glucose carrier protein (Bonina et al. 2000, Battaglia et al. 2000). Also 
in the study by Polt et al. (1994) it was hypothesized that the attachment of β-D-glucose 
moiety to an enkephalin analogue would be one way to increase the transfer of the peptide 
across the BBB since after peripheral administration of the compound, significant analgesia 
was achieved. In addition to LAT1 and glucose transporters, the ascorbate transporter has 
been studied as a possible route through which to deliver drugs into the CNS (Manfredini et 
al. 2002). 
 
   The concept of efflux inhibition has been mainly used to enhance the CNS delivery of anti-
tumour or anti-HIV agents. Fellner et al. (2002) have demonstrated using nude mice that the 
brain entry and the therapeutic effect of paclitaxel could be enhanced by simultaneous 
administration of a P-gp inhibitor valspodar. In addition, another P-gp inhibitor, GF120918 
was demonstrated to increase the CNS entry of drugs including nelfinavir, morphine and 
amprenavir in rats or mice (Polli et al. 1999, Savolainen et al. 2002, Letrent et al. 1999). 
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   Probenecid which is a non-specific inhibitor of various transporters at the blood-CNS 
barriers has been shown to increase the brain concentrations of dideoxynucleosides in rats 
(Galinsky et al. 1991). In patients with bacterial meningitis, co-administration of probenecid 
increased the CSF levels of amoxicillin and may have had an effect on elimination of 
amoxicillin from the CSF (Craft et al. 1979).  
 
   Research in the field of efflux inhibitors has suffered from the lack of specific inhibitors. 
For instance, the commonly used efflux inhibitor probenecid is extremely non-specific which 
complicates the interpretation of the results from preclinical studies. Other problems related to 
the clinical use of efflux inhibitors include the possibility that the inhibitor may alter the 
pharmacokinetic properties of the drug, leading to potential toxicity. It is also possible that 
high doses of inhibitors may be required in order to obtain efflux inhibition; often very high 
concentrations have been used in pre-clinical studies to illustrate the effects of efflux 
inhibitors. The requirement of a high dose may impede the clinical use of efflux inhibitors. In 
addition, the ability of efflux inhibition to enhance the CNS delivery of an efflux protein 
substrate may be rather limited (Kalvass and Pollack 2007).  
2.1.4 Experimental models for studying central nervous system drug delivery 
   In vitro BBB models include isolated brain capillaries, primary or low passage brain 
capillary endothelial cell cultures, immortalized brain endothelial cells and immortalized 
artificial membranes (Gumbleton and Audus 2001, Nicolazzo et al. 2006). Of the endothelial 
cell cultures, cells from bovine and porcine sources are the most commonly used. Cells of 
non-cerebral origin have also been used but they may suffer from serious limitations. For 
instance, it has been suggested that the human colon carcinoma cell line (Caco-2) predicts 
poorly the in vivo BBB permeability (Lundquist et al. 2002). The basic principle of an in vitro 
BBB model suitable for studying general mechanisms of transport through endothelial cells is 
presented in Figure 2.5. 
 
   Obviously, the greatest challenge is to develope a model which faithfully and accurately 
replicates the in vivo conditions, e.g. the same kind of integrity as the BBB and same amount 
and composition of transport proteins and enzymes. Pardridge et al. have studied the 
correlation between drug transport across primary cultures of bovine brain capillary 
endothelial monolayers and BBB permeability after brain perfusion. According to their 
results, there is a strong correlation between permeability values measured in endothelial 
monolayers and after brain perfusion. However, the permeability values in the in vitro system 
were on average about 150-fold greater than those determined after brain perfusion (Pardridge 
et al. 1990). This correlation did not apply to drugs that pass across the BBB via carrier 
mediated transport indicating that there had been a loss of activity of transport proteins in the 
in vitro system.  
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   In order to improve the tightness of the in vitro BBB models, astrocyte-conditioned medium 
or co-culture with astrocytes has been used (Gumbleton and Audus 2001). The so-called 
conditionally immortalized cells may also represent a useful tool in CNS drug delivery 
research, especially when transport systems are concerned (Terasaki et al. 2003).   
 
 
Figure 2.5. Diagram of the basic principle of an in vitro BBB model. Endothelial cells are 
grown on microporous membranes. Astrocytes can be grown on the underside of the same 
membrane or on the bottom of the chamber to release soluble factors, which preserve some of 
the BBB properties. The test compounds can be added to the luminal or to the abluminal 
compartment, and bidirectional transport across the BBB can be studied. 
 
   In vivo and in situ the BBB permeability studies can be basically carried out through two 
different approaches; the single pass uptake approach and the continuous uptake approach 
(Smith 1989). In the single pass uptake approach, the brain uptake or extraction of a drug is 
determined after a bolus injection into the carotid artery followed by its single pass through 
cerebral capillaries. Techniques most often used to evaluate the influx of drugs into the brain 
using the single pass uptake approach include the indicator diffusion technique, the brain 
uptake index (BUI) technique and the single injection-external registration technique. 
Common to all these techniques is their relative simplicity but one major disadvantage of 
these methods is their limited sensitivity due to the short uptake time (5-15 seconds). A 
scheme of the most representative single pass uptake method, BUI, in presented in Figure 2.6. 
The continuous uptake approach overcomes the sensitivity-problems of the single pass uptake 
approach since the uptake can be measured over a prolonged period of time. The two basic 
techniques used to evaluate the influx of drugs into the brain using the continuous uptake 
approach are the intravenous administration technique and the brain perfusion technique. 
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Since these techniques have been utilized in the present study they are discussed in more 
detail in the following chapters. 
 
 
 
Figure 2.6. In the BUI method, the drug is injected as a bolus dose into the common carotid 
artery together with a freely permeable internal standard. The arrows represent the diffusion 
of the test mixture in the plasma compartment. The internal standard is used to define the 
amount of injected mixture which reaches the brain. At 5-15 seconds post-dose, the brain is 
removed and the brain uptake of the drug is determined by the ratio of the internal standard to 
drug in the brain to the ratio of the internal standard to drug in the dosing mixture. (Bonate 
1995) 
 
   Some of the techniques used to estimate the brain uptake of drugs can also be used to 
studying the efflux of drug from brain to blood. For instance, the modified version of the 
brain uptake index technique (Bonate 1995) and in situ brain perfusion technique (Chikhale et 
al. 1995) have been utilized in efflux studies. The brain efflux index technique, where the test 
compound and an impermeable reference compound are microinjected directly into the brain 
and their brain concentrations are measured over time, has also been used for studying efflux 
mechanisms at the BBB (Kakee et al. 1997). 
2.1.4.1 In situ brain perfusion technique 
   The in situ brain perfusion method was originally described by Takasato et al. in 1984 
(Takasato et al. 1984). In this method, the right cerebral hemisphere of a rat is perfused by 
retrograde infusion of perfusion fluid into the right external carotid artery (Figure 2.7). The 
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perfusion rate is adjusted so that the effect of systemic blood flow to the right hemisphere is 
minimized and that the carotid perfusion pressure is maintained below the 160-190 mmHg 
threshold that damages the BBB. At predetermined times, brain tissue is collected and the 
amount of the compound is determined. Finally, the brain uptake kinetics can be analyzed and 
transport or permeability constants can be calculated.  
 
   Subsequently the Takasato method was modified by several research groups. For instance, 
in the modification described by Smith and Allen (2003) the method became surgically less 
time-consuming as the perfusion fluid catheter was inserted into the common carotid artery, 
followed by ligation of the external carotid artery (Figure 2.7). The pterygopalatine artery 
could either be ligated or left open. In addition, in the modified method, blood flow from the 
systemic circulation is stopped by severing cardiac ventricles at the beginning of the 
perfusion. This modification makes the method less vulnerable to the perfusion flow rate as 
there is no contribution to flow from the systemic circulation. Prior to perfusion, the blood 
supply to the brain is maintained via the crossover of blood from the contralateral carotid 
artery at the Circle of Willis (Figure 2.7). 
 
   The modification introduced by Triguero et al. (1990) incorporated the possibility to 
differentiate between a transcytosed compound from simple binding and/or endocytosis of the 
compound by brain capillary endothelium. The method referred to as the capillary depletion 
method used a dextran density centrifugation step to deplete brain homogenate of the 
vasculature.      
 
   The most crucial advantage of the in situ brain perfusion method is the ability to control the 
composition of the perfusion fluid. This allows the investigation of carrier-mediated transport 
mechanisms at the BBB as well as the effect of plasma protein binding. The perfusion fluid 
can be manipulated in many ways such as through changes in the solute concentrations, pH, 
osmolality, ionic contents and protein compositions. In addition, there is little (< 5%) or no 
contribution of systemic blood flow to the perfused hemisphere and the contribution of 
peripheral pharmacokinetics is avoided (Takasato et al. 1984). 
 
   The disadvantages related to the in situ brain perfusion method include the impossibility to 
control the drug concentration in brain extracellular fluid, the need for an appropriate 
analytical assay for the determination of drug concentration in brain tissue, possible 
disruption in the physiological function of the BBB during the experiment and the use of 
analgesics during the experiment which may modify the results (Smith 1996). 
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A 
 
 
 
B 
 
Figure 2.7. A. In original Takasato method (1984), the occipital and superior thyroid arteries 
are coagulated and cut, and the right pterygopalatine artery is ligated. The external carotid 
artery is catheterized and the common carotid artery is ligated immediately prior to the 
perfusion.  B. In the modified method by Smith and Allen (2003) the common carotid artery 
is catheterized and the external carotid artery is ligated. The pterygopalatine artery is ligated 
or it can be left undisturbed.  
2.1.4.2 Intravenous administration technique 
   In the intravenous administration technique, the drug is injected intravenously as a bolus 
injection or as a constant infusion, and the amount of the drug in brain is measured after a 
predetermined time. Simultaneously with the brain sampling, a blood sample is collected in 
order to detect the whole blood or plasma concentration of the drug. The uptake time can 
range from about 10 seconds to as long as several hours, depending on the brain permeability 
Circle of Willis 
Anterior Cerebral A. 
Middle  
Cerebral A. 
Posterior  
Cerebral A. 
Basilar A. 
Vertebral A. 
Pterygopalatine A. 
Common Carotid A. 
Internal  
Carotid A. 
External Carotid A. 
Perfusate  
Circle of 
Willis 
Anterior Cerebral A. 
Middle  
Cerebral A. 
Posterior  
Cerebral A. 
Basilar A. 
Vertebral A. 
Pterygopalatine A. 
Common Carotid A. 
Internal  
Carotid A. 
External Carotid A. 
Perfusate  
Superior  
Thyroid A. 
Occipital A. 
36 
 
properties of the drug (Smith 1989). The amount of the drug in brain tissue can be determined 
after tissue sampling followed by a suitable analytical technique or by different imaging 
techniques, and finally, the BBB permeability can be calculated using kinetic models. In 
addition to BBB pharmacokinetics, also the systemic pharmacokinetics can be obtained, this 
being regarded as one of the main advantages of this technique (Bickel 2005). The possibility 
to infuse drugs to steady-state further increases the value of the intravenous administration 
technique. In addition, the intravenous administration technique allows the evaluation of the 
CSF permeation of drugs since in addition to the blood and brain tissue sampling, the CSF 
can be collected at predetermined times. 
 
   Intravenous administration technique models most closely mimic the in vivo situation as the 
BBB is intact and the functions of various transporters, enzymes etc. both at the BBB as well 
as in the periphery are not compromised (Bickel 2005). On the other hand, the presence of 
metabolism and peripheral pharmacokinetics may complicate the application of the technique 
and the interpretation of the results obtained using the technique. For instance,  differentiating 
between unidirectional and bidirectional transport can be a great challenge (Bickel 2005).  
2.1.4.3 Other experimental models for studying central nervous system drug delivery 
   One of the most recent and important additions to the battery of in vivo methods available to 
study CNS delivery is the intracerebral microdialysis technique. This technique involves the 
stereotactic implantation of a semipermeable microdialysis probe into the brain, and the drug 
concentration in the ECF compartment of the brain is determined by monitoring the drug 
concentration in the perfusate that flushes the microdialysis probe (Figure 2.8). With the 
intracerebral microdialysis technique, studying both influx and efflux mechanisms of drugs in 
freely moving animals is possible, and concentrations in brain ECF, CSF or blood can be 
measured simultaneously and furthermore, they represent directly the unbound concentration 
of the drug (Hammarlund-Udenaes 2000). Other advantages of this method include the 
possibility to obtain a concentration-time course of the test compound from individual 
subjects, and the possibility to determine local drug concentration in the CNS, as the probe 
can be placed in any region of the brain (de Lange et al. 1999). The limitations with the 
intracerebral microdialysis method include the potential disruption of the BBB resulting from 
the probe implantation, the requirements for the assay method (adequate sensitivity) and the 
need for assessing the relationship between dialysate concentrations and the brain ECF 
concentrations (the so called in vivo concentration recovery) (de Lange et al. 1999). 
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Figure 2.8. Schematic drawing of the principle of microdialysis. The microdialysis probe is 
implanted into brain and the semipermeable membrane is perfused with a physiological 
solution at a constant flow rate. The diffusion of compounds occurs according to the 
concentration gradient. 
 
   In addition, imaging techniques such as quantitative autoradiography, magnetic resonance 
imaging (MRI), positron emission tomography (PET) and single photon computed 
tomography (SPECT) expand greatly the selection of methods which can be used in the area 
of CNS research because the noninvasive techniques MRI, PET and SPECT can also be 
applied in humans (Bickel 2005). Finally, in silico models which could accurately predict the 
CNS permeation of drugs are eagerly awaited. In particular, the modeling of the CNS 
permeation of drugs which are substrates for influx and efflux transporters at the blood-CNS 
barriers is currently impossible. The development of reliable models with good abilities to 
predict the CNS permeation of all kinds of drugs requires most of all the collation of more 
experimental brain permeation data to make the modeling more comprehensive (Clark 2003).  
 
   In summary, owing to the complexity of the CNS and the multiplicity of the factors that 
influence the CNS uptake of drugs, it is an enormous challenge to develop an ideal 
experimental model for studying the CNS drug delivery. Typically, compromises have to be 
made in order to model faithfully the in vivo situation and yet to retain adequate simplicity 
 
Semipermeable 
membrane 
Perfusate 
Dialysate 
Compound of 
interest 
Brain ECF 
38 
 
and practicality. Often, the combined use of in vivo, in situ and in vitro models is of great 
value (Johanson et al. 2005).  
2.2 Non-steroidal anti-inflammatory drugs 
2.2.1 Physicochemical and pharmacokinetic properties of ibuprofen, ketoprofen and 
indomethacin  
   NSAIDs are a chemically heterogeneous group of compounds which share common 
pharmacological effects. Ibuprofen and ketoprofen belong to the group of propionic acid 
derivatives whereas indomethacin is an acetic acid derivative (Figure 2.9). Some 
physicochemical properties of ibuprofen, ketoprofen and indomethacin are shown in Table 
2.2. 
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Figure 2.9. Structures of ibuprofen (A), ketoprofen (B) and indomethacin (C). 
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Table 2.2. Molecular weight, pKa and logP values of ibuprofen, ketoprofen and 
indomethacin. 
Compound Molecular 
weight 
pKaa logPa Apparent logP (pH 7.4) 
Calculatedb Experimentally determined 
Ibuprofen 206 4.41 3.72 0.73 0.98 (Austin et al. 2002)  
1.07 (Barbato et al. 1997) 
Ketoprofen 254 4.23 2.81 -0.36 -0.09 (Austin et al. 2002)  
-0.25 (Barbato et al. 1997)  
-0.2 (Rautio et al. 1998) 
Indomethacin 358 4.17 3.11 -0.12 0.89 (Austin et al. 2002)  
0.91 (Barbato et al. 1997) 
 
a. Advanced Chemistry Development (ADC/Labs) Software Solaris V4.67 
b. Calculated according to equation 



+
−=
−pKapH4.7 101
1logPlogPlog  
 
   Most NSAIDs, including ibuprofen, ketoprofen and indomethacin, are rapidly absorbed 
from the gastrointestinal tract after oral administration. Peak plasma concentrations of 
ketoprofen and indomethacin are reached within 1-2 hours (Burke et al. 2006, Hucker et al. 
1966, Ishizaki et al. 1980, Upton et al. 1981). Ibuprofen has been shown to reach a peak 
plasma concentration as quickly as 15-30 minutes after oral administration (Lee et al. 1985). 
In addition, absorption of these three NSAIDs is virtually complete. 
 
   In the circulation, ibuprofen, ketoprofen and indomethacin are extensively bound to plasma 
albumin. The unbound fraction of ibuprofen, ketoprofen and indomethacin is less than 1% in 
humans determined in vitro by equilibrium dialysis at 37○C (Netter et al. 1985, Bannwarth et 
al. 1990, Bannwarth et al. 1995). It has been suggested that ibuprofen and ketoprofen bind 
with high affinity to site II in human serum albumin whereas indomethacin binds to site I 
(Kragh-Hansen et al. 2002). Ibuprofen, ketoprofen and indomethacin have volumes of 
distribution of about 0.2, 0.1 and 0.3 l/kg, respectively (Burke et al. 2006, Upton et al. 1981). 
The estimated plasma half-life of indomethacin in humans after oral administration is about 2 
hours (Hucker et al. 1966). However, presumably due to the enterohepatic cycling of 
indomethacin and its metabolites, a terminal half-life as long as 120 h has been described. 
However, this long half-life may be of no clinical relevance (Buxton 2006). The estimated 
plasma half-life of ketoprofen in humans is about 1.5 hours (Ishizaki et al. 1980, Upton et al. 
1981) and that of ibuprofen about 2 hours (Lee et al. 1985). In rats the apparent half-lives of 
indomethacin and ketoprofen has been suggested to be about 4 and 10 hours, respectively, i.e. 
longer than in humans (Hucker et al. 1966, Foster and Jamali 1988, Satterwhite and Boudinot 
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1992), but the apparent half-life of ibuprofen has been suggested to be comparable in rats and 
humans (Satterwhite and Boudinot 1991). 
 
   Hepatic biotransformation and renal excretion are the main elimination pathways of the 
majority of NSAIDs in humans (Verbeeck 1990). Metabolism of indomethacin includes O-
demethylation (50%), conjugation with glucuronic acid (10%), and N-deacylation (Burke et 
al. 2006). Indomethacin is excreted in the bile, reabsorbed and finally excreted in the urine 
(Hucker et al. 1966). The metabolism of ketoprofen involves the formation of acyl 
glucuronides, which are excreted in the urine (Ishizaki et al. 1980). Acyl glucuronides are 
unstable in physiological conditions and since they can be hydrolyzed back to the parent 
compound, accumulation of the acyl glucuronide metabolite of ketoprofen in the plasma can 
significantly delay the elimination of ketoprofen (Verbeeck 1990). Ibuprofen is mainly 
metabolized to hydroxylate or carboxylate derivatives (Burke et al. 2006). The renal excretion 
of unmetabolized ibuprofen, ketoprofen and indomethacin is a minor elimination pathway. 
Less than 1% of ibuprofen, 10% of ketoprofen and between 5 to 20% of indomethacin are 
excreted in an unchanged form (Burke et al. 2006, Hucker et al. 1966, Ishizaki et al. 1980). 
2.2.1.1 Central nervous system permeation  
   Preclinical studies evaluating the CNS permeation of NSAIDs vary in the species used in 
the study, administration route, dose, and methods for measuring and evaluating the CNS 
uptake. In general, the in vivo CNS permeation of NSAIDs is believed to be quite limited. 
Table 2.3 shows some experimental data concerning the CNS permeation of NSAIDs in 
rodents. 
 
Table 2.3. Experimental data on CNS permeation of NSAIDs in rodents. 
 
NSAID 
 
Study protocol 
 
Outcome 
 
Ref. 
Ketoprofen  I.p. administration (5 mg/kg) in 
rats, blood and CSF samples 
collected 0.5-24 h after 
administration. 
 
AUCCSF / AUCplasma, total ratio:  
0.006 
(Matoga et 
al. 2002) 
Naproxen 
Flurbiprofen 
I.v. bolus (6 mg/kg) in rats, blood 
and brain tissue samples collected 
10 and 60 min after administration. 
 
Brain / plasma ratio (10; 60 min)a: 
Naproxen: 0.014; 0.017  
Flurbiprofen: 0.005; 0.004 
(Frijlink et 
al. 1991) 
Ketoprofen I.v. administration (40 µmol/kg) in 
mice, blood and brain tissue 
samples collected 1-60 min after 
administration. 
 
In situ brain perfusion (10-60 s) in 
mice with buffer containing 30 µM 
ketoprofen and BSA. 
 
AUCCSF / AUCplasma ratio: 0.017a 
 
 
 
 
CLin: 0.0308 ml/min/g 
(Deguchi et 
al. 2000) 
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Table 2.3. continued… 
 
NSAID 
 
Study protocol 
 
Outcome 
 
Ref. 
Ketoprofen 
Carprofen 
Fenoprofen 
Flurbiprofen 
Ibuprofen 
Naproxen 
Suprofen 
Tiaprofenic acid 
I.p. administration (5 mg/kg) in 
rats, blood and CSF samples 
collected 0.5-6 h after 
administration. 
AUCCSF / AUCprotein-free plasma ratio:  
Ketoprofen: 0.64 
Carprofen: 0.23 
Fenoprofen: 4.79 
Flurbiprofen: 5.31 
Ibuprofen: 1.44 
Naproxen: 0.96 
Suprofen: 0.81 
Tiaprofenic acid: 0.79 
 
(Pehourcq et 
al. 2004) 
Ibuprofen 
Flurbiprofen 
Indomethacin  
In situ brain perfusion (10-30 s) in 
rats with buffer containing 0.54, 
0.15; and 2.5 µM of ibuprofen, 
flurbiprofen and indomethacin, 
respectively and 0 or 2.7% BSA. 
BBB PSu-value from buffer: 
Ibuprofen: 2.63 x 10-2 ml/s/g 
Flurbiprofen: 1.60 x 10-2 ml/s/g 
Indomethacin: 0.64 x 10-2 ml/s/g 
 
2.7% BSA decreased the brain 
uptake 95% 
 
(Parepally et 
al. 2006) 
Naproxen 
Ketoprofen 
Diclofenac 
Piroxicam 
Fenoprofen 
Sulindac 
Ibuprofen 
Flurbiprofen 
Meclofenamic acid 
P.o. (50 mg/kg/day) for 3 days in 
Tg2576 transgenic mice. 
Brain / plasma concentration ratioa: 
Naproxen: 0.02 
Ketoprofen: 0.02 
Diclofenac: 0.08 
Piroxicam: 0.18 
Fenoprofen: 0.02 
Sulindac: 0.03 
Ibuprofen: 0.05 
Flurbiprofen: 0.03 
Meclofenamic acid: 0.03 
 
(Eriksen et 
al. 2003) 
Celecoxib P.o. (50 or 100 mg/kg/day) for 3 
days in mice. 
Brain / plasma concentration ratio: 
3.0 and 2.4 for the dose of 50 and 
100 mg/kg/day, respectively. 
 
(Kukar et al. 
2005) 
Ibuprofen 
R-flurbiprofen 
Indomethacin 
Naproxen 
Sulindac sulfide 
Mefanamic acid 
Fenoprofen 
Methylflurbiprofen 
P.o. (50 mg/kg) in mice. Drug 
levels measured at Tmax. 
Brain / plasma concentration ratio: 
Ibuprofen: 0.03 
R-flurbiprofen: 0.04 
Indomethacin: 0.01 
Naproxen: 0.03 
Sulindac sulfide: 0.006 
Mefanamic acid: 0.03 
Fenoprofen: 0.03 
Methylflurbiprofen: 0.02 
 
(Stock et al. 
2006) 
Indomethacin 
 
P.o. (3.5 mg/kg) in rats, blood and 
brain samples collected 2-24 h 
after administration. 
 
Brain / plasma concentration ratio: 
0.02 
AUCbrain / AUCplasma ratio:  0.03 
(Dvir et al. 
2006) 
Indomethacin 
 
P.o. and  i.v. infusion (3.5 mg/kg) 
in rats, blood and brain samples 
collected 8 h after administration. 
 
Brain / plasma concentration ratio: 
P.o.: 0.03 
I.v.: 0.08 
 
(Dahan and 
Hoffman 
2007) 
a Calculated from data shown in ref. 
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 With the exception of the occasional case studies of fatal overdoses of NSAIDs (Kunsman 
and Rohrig 1993), the CNS permeation of NSAIDs in humans has been studied only by 
measuring the CSF concentration of the drug after a single-dose administration in adults 
(Table 2.4). Studies with indomethacin (Bannwarth et al. 1990), ketoprofen (Netter et al. 
1985), ibuprofen (Bannwarth et al. 1995) and ketorolac (Rice et al. 1993) as well as 
experiments with COX2-selective agents, celecoxib, rofecoxib and valdecoxib (Dembo et al. 
2005) demonstrate that these drugs enter the CSF. The average CSF to total plasma 
concentration ratio or the CSF to total plasma AUC ratio of indomethacin, ketoprofen, 
ibuprofen and ketorolac ranges from 0.00046 to 0.015, and the peak CSF concentration is 
achieved 2-4 hours after intramuscular or oral administration. Interestingly, rofecoxib exhibits 
higher maximum CSF to total plasma concentration ratio than the other coxibs or non-
selective NSAIDs. However, when CNS penetration was evaluated based on CSF to unbound 
drug concentration ratio, no differences were found between different coxibs (Dembo et al. 
2005).   
 
   In general, studying the CSF concentrations of NSAIDs is rather difficult. Firstly, the CSF 
compartment is difficult to access and for ethical reasons, usually only one sample is collected 
from each patient. This kind of protocol is not optimal for studying the pharmacokinetics of 
compounds, but it is generally believed to produce valuable data about the CSF permeation of 
drugs (Sheiner 1984, Fowler and Dawes 1985).  Secondly, the permeation of NSAIDs into the 
CSF is limited which places major demands on the analytical methods to be used.  
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Table 2.4. Experimental data on CNS permeation of NSAIDs in humans. 
 
NSAID 
 
Outcome 
 
Ref. 
 
 
Mean CSF / plasma 
concentration ratioa 
Maximun CSF/ plasma 
concentration ratio 
Cmax and  
tmax in CSF 
 
 Plasma, 
total 
Plasma, 
unbound 
Plasma,  
total 
Plasma, 
unbound 
  
Indomethacin  
50 mg i.m., plasma 
sampling  
0.5-12 h post-dose 
 
0.0074 1.44 0.029 
(7 h post-
dose) 
 
(0.012d) 
4.27 
(4 h post-
dose) 
 
(2.90f) 
11.9 ng/ml 
(5.1 ng/mld) 
 
2 h 
(Bannwarth 
et al. 1990) 
 
Ketoprofen  
100 mg i.m., 
plasma sampling  
0.25-13 h post-dose 
 
 
0.011 
 
0.81 
 
0.06 
(13 h post-
dose) 
 
(0.029e) 
 
2.50 
(5 h post-
dose) 
 
(n=1) 
 
18 ng/ml 
(14 ng/mlf) 
 
4 h 
 
(Netter et al. 
1985) 
 
Ketorolac  
90 mg i.m., plasma 
sampling  
1-4.5 h post-dose 
 
0.00046 
 
0.057 
 
0.0018 
 
(4.5 h post-
dose) 
 
0.23 
 
(4.5 h post-
dose) 
 
5.7 ng/ml 
 
2.5 h 
 
(Rice et al. 
1993) 
 
Celecoxib 
200 mg p.o.b 
 
 
Rofecoxib  
50 mg p.o.b 
 
 
Valdecoxib  
40 mg p.o.b 
 
Plasma sampling  
0.5-10 h post-dose 
 
- 
 
 
 
- 
 
 
 
- 
 
1.5 – 1.7 
for all 
coxibsg 
 
 
 
 
 
 
 
0.008c 
 
 
 
0.20c 
 
 
0.040c 
 
 
(6 h post-
dose) 
 
 
- 
 
 
 
- 
 
 
- 
 
 
 
 
 
2.4 ng/mlc 
4.3 hc 
 
 
56.6 ng/mlc 
4.4 hc 
 
 
9.7 ng/mlc 
4.8 hc 
 
 
 
(Dembo et 
al. 2005) 
   
 
 
Mean AUCCSF / AUCplasma ratio 
 
  
 Plasma, total Plasma, unbound   
Ibuprofen  
800 mg p.o., 
plasma sampling  
0.5-8 h post-dose 
 
R-ibuprofen: 0.009 
 
S-ibuprofen: 0.015 
R-ibuprofen: 3.6 
 
S-ibuprofen: 3.3 
R-ibuprofen: 
168 ng/ml 
 
S-ibuprofen:  
315 ng/ml 
3 h 
(Bannwarth 
et al. 1995) 
a Calculated from data shown in ref. 
b All three drugs dosed together. 
c.Mean of nine subjects. 
d Mean of four subjects at the same time point. 
e Mean of six subjects. 
f Mean of three subjects. 
g Individual data not provided 
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2.2.1.2 Interactions with endogenous transport mechanisms 
   It has been suggested that NSAIDs interact with various transport mechanisms in the body. 
For instance, it is known that NSAIDs can interact with OATs expressed in Xenopus laevis 
oocytes (Apiwattanakul et al. 1999, Mulato et al. 2000). At the level of the BBB and the 
BCSFB, there might also be interactions between NSAIDs and transporters for organic 
anions.  
 
   Deguchi et al. (2000) have studied the brain delivery of ketoprofen and its triglyceride 
prodrug using a variety of in vivo and in situ methods in mice. One interesting observation 
was that ketoprofen may be transported from the brain back to the blood circulation via the 
efflux system for organic anions. In addition, Ohtsuki et al. (2002) have discovered that 
ketoprofen is able to inhibit significantly indoxyl sulfate uptake by OAT3 in a Xenopus 
oocyte expression system. This suggests that ketoprofen may be a substrate for this transport 
protein. Consequently, it is possible that the apparently poor CNS distribution of ketoprofen is 
partly due to efflux mechanisms at the blood-CNS barrier. In situ brain perfusion studies with 
rats have also indicated that the brain uptake of ibuprofen is partly carrier-mediated since the 
BBB ibuprofen transport was saturable and could be inhibited by indomethacin (Parepally et 
al. 2006). 
2.2.2 Peripheral and central actions of non-steroidal anti-inflammatory drugs 
   NSAIDs are used as anti-inflammatory, analgesic and antipyretic agents. They are indicated 
to treat mild or moderate pain following injury or disease. They also have an important role in 
treating chronic pain states in e.g. arthritis (Burke et al. 2006). In severe pain, e.g. after 
surgery, they are advantageous when combined with opioids (Kokki 2003). NSAIDs are 
believed to act mainly through inhibition of prostaglandin synthesis (Vane 1971). A key 
enzyme in the synthesis of prostaglandins is prostaglandin endoperoxide G/H synthase, more 
commonly called cyclooxygenase (COX) (Smyth et al. 2006). There are at least two forms of 
COX, COX1 and COX2, which have different localisations and functions. It is believed that 
COX2 is induced in inflammatory conditions whereas COX1 is a constitutive enzyme found 
in almost all cells. However, COX2 is also expressed constitutively in some tissues, including 
the brain (Kaufmann et al. 1997), and it seems that both isoenzymes have physiological and 
pathological roles (Loftin et al. 2002). Most clinically used NSAIDs inhibit both isoenzymes, 
only the degree of selectivity varies.  
2.2.2.1 Antihyperalgesic effects  
   Nociceptors or pain receptors are receptors for injurious or painful stimuli. In inflammation, 
various inflammatory mediators interact with nociceptors causing pain. Prostaglandins can act 
as sensitizing agents for enhancing the nociceptive properties of these inflammatory 
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mediators, and this is the reason why inhibition of prostaglandin synthesis is able to evoke an 
antinociceptive effect. The antinociceptive effect of NSAIDs can be described better as being 
antihyperalgesic rather than as analgesic because NSAIDs, through inhibiting prostaglandin 
formation, reverse the increase in response to noxious stimuli and the appearance of 
spontaneous activity in the nociceptors, the hallmarks of inflammatory pain, rather than 
elevating the normal pain threshold (Burian and Geisslinger 2005). 
 
   The antinociceptive effects of NSAIDs are usually believed to be mediated mainly in 
peripheral tissues. However, it has been claimed that NSAIDs act also at the central level 
(Ossipov et al. 2000, Malmberg and Yaksh 1992, Daher and Tonussi 2003). The central 
mechanism of action of NSAIDs has been established e.g. by administering NSAIDs directly 
into the CNS in animal models of inflammatory pain.  For example, Malmberg and Yaks 
(1992) have studied the antinociceptive potency and efficacy of various NSAIDs after 
intrathecal administration. According to their studies, NSAIDs displayed dose-dependent 
antinociceptive actions in the rat after intrathecal administration which they proposed was 
evidence for the existence of a central mode of action. The potencies varied considerably 
between different NSAIDs. NSAIDs also reduced nociceptive behaviour after intraperitoneal 
administration, but the agents were 100 to 1000 times more potent after spinal than after 
intraperitoneal administration. For instance, indomethacin had ID50 values of 1.9 nmol after 
intrathecal delivery compared to 2600 nmol after intraperitoneal administration. The ID50 
value represents the dose resulting in 50% inhibition of the control response in the formalin 
test.  
 
   In conclusion, according to our present understanding, the antihyperalgesic effect of 
NSAIDs takes place both at the peripheral and central levels. The relative contribution of the 
two components depends on the particular NSAID used, the site of drug delivery and how the 
drug reaches its site of action (Burian and Geisslinger 2005). With respect to the central 
actions of NSAIDs, the drug levels in brain or spinal tissue are critical. However, at present, 
there is inadequate data on the CNS distribution of NSAIDs after therapeutic administration. 
Accordingly, it is not understood how the drug levels in the CNS after experimental local 
administration directly into the CNS and after therapeutic systemic administration correspond 
to each other.   
2.2.2.2 Alzheimer's disease and non-steroidal anti-inflammatory drugs 
   AD is the most common cause of dementia in the elderly. It is a progressive 
neurodegenerative disorder which eventually causes death. It is traditionally characterized 
neuropathologically by the presence of senile plaques, neurofibrillary tangles, cerebral 
amyloid angiopathy and loss of neurons (Selkoe 2001). After reports that people suffering 
from inflammatory diseases, such as rheumatoid arthritis, had a lower incidence of AD, there 
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has been interest towards the potential of using NSAIDs as a means to achieve AD 
prevention. 
 
   AD is a disease which has been extensively investigated and for example, some genetic 
factors underlying the disease have been identified. These include mutations in β-amyloid 
precursor protein and presenillins which are responsible for the rather infrequent familial 
forms of AD, and the presence of the apolipoprotein ε4 allele, which is a major risk factor for 
the disease (Selkoe 2001). However, the exact pathogenesis of AD is not completely 
understood. It is, for example, recognized that amyloid β (Aβ) peptide, a primary component 
of senile plaques, has a crucial role in the development of AD pathology but whether it 
actually is causing the disease, is far from clear. It is also known that chronic 
neuroinflammation occurs in the AD brain. At the cellular and molecular levels, inflammation 
can be seen as the presence of activated microglia and reactive astrocytes and altered 
concentrations of various pro- and anti-inflammatory mediators (Akiyama et al. 2000).    
 
   The onset of AD is insidious and it is generally believed that the disease begins decades 
before any clinical symptoms are detected. It is evident that this first, latent phase of the 
disease would represent the best time to initiate some kind of prevention or treatment strategy 
(Zandi and Breitner 2001). To date, several epidemiological studies have provided clear 
evidence that the use of NSAIDs may reduce the risk or delay the onset of AD (Etminan et al. 
2003, Szekely et al. 2004, Vlad et al. 2008). This epidemiological evidence together with the 
recognition that neuroinflammation may have a role in the pathogenesis of AD and the 
emerging need for preventive strategies against the disease has represented the rationale 
behind a series of laboratory studies with NSAIDs. Despite much work done with both cell 
cultures and animal models (Townsend and Pratico 2005, Gasparini et al. 2004), the exact 
mechanisms of action by which NSAIDs may be able to modify AD have not yet been 
described. In addition to COX-inhibition, it has been suggested that the beneficial effects of 
some NSAIDs in AD could be mediated by interactions with nuclear factor-κB and 
peroxisome proliferator-activated receptor-γ and subsequent reduction in inflammatory 
processes, as well as direct anti-amyloid mechanisms.  To date, only a few randomised, 
controlled clinical trials have been conducted with NSAIDs but unfortunately, they have not 
been encouraging. For instance, although a small pilot trial with indomethacin did show 
positive results (Rogers et al. 1993), more recent studies with larger populations investigating 
the effect of rofecoxib and naproxen in combating the progress of AD produced negative 
results (Reines et al. 2004, Aisen et al. 2003). 
 
   According to the in vitro data, studies with transgenic animal models and clinical trials, it 
has been proposed that only some of the NSAIDs have AD modifying properties. For 
instance, it has been argued that only COX-nonselective NSAIDs rather than the COX-
selective agents have beneficial effects against AD (Townsend and Pratico 2005). In addition, 
NSAIDs may be efficient in preventing rather than treating the disease. In order to 
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demonstrate the usefulness of NSAIDs in treating or preventing AD, prospective, long-term 
prevention trials will be required. To attain full advantage from such a study, several aspects 
in the study design will have to be taken into account - for example COX-selectivity and anti-
amyloidogenic properties of the drug, brain penetration properties of the drug, the dose, since 
COX-independent mechanisms are only achieved at high drug concentration in vitro, duration 
of the treatment, as it has been suggested that the exposure to NSAIDs should be at least 2 
years in duration in order to produce beneficial effects (Stewart et al. 1997, in t' Veld et al. 
2001), and the stage of the disease at the onset of treatment, since people already diagnosed 
with AD may have suffered neuronal damage that is too advanced to obtain any clinical 
benefit from  NSAIDs. 
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3 AIMS OF THE STUDY 
 
   The rationale for the present thesis emerged from the need to understand better the CNS 
permeation and distribution properties of NSAIDs. The CNS availability of NSAIDs is of 
interest because NSAIDs may have clinically significant CNS actions related to central 
antinociception and prevention or treatment of neurodegenerative diseases such as AD. 
However, the CNS permeation of NSAIDs and the factors affecting the disposition of their 
CNS delivery are not fully understood. We hypothesized that the CNS permeation of 
traditional, widely used NSAIDs ibuprofen, indomethacin and ketoprofen is limited after 
systemic administration when the extent of the CNS permeation is evaluated based on the 
ratio between the brain or the CSF concentration and the plasma concentration. Therefore, the 
main aim of the present study was to evaluate the CNS permeation of three NSAIDs, 
ibuprofen, ketoprofen and indomethacin.  
 
   The main aim was divided into two parts; the first aim was to evaluate the CNS 
permeation of ibuprofen and indomethacin in rats by measuring the drug concentrations in 
brain tissue homogenate after intravenous infusion or after perfusion via the carotid artery. 
The second aim was to evaluate the CSF permeation of ketoprofen and indomethacin in 
children after intravenous injection. 
 
   Implementation of the experiments required the refinement of the constant in vivo 
infusion method and an in situ brain perfusion method in rats. The determination of 
ibuprofen, indomethacin and ketoprofen from biological samples, which included brain tissue 
homogenate, CSF, plasma and protein-free plasma, required the development and the 
verification of the reliability of the sample pre-treatment as well as HPLC and GC-MS 
methods. 
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4 CNS PERMEATION OF IBUPROFEN AND INDOMETHACIN IN RATS* 
Abstract. Chronic use of NSAIDs may reduce the risk or delay the onset of Alzheimer’s 
disease. To date, only limited information exists on the brain distribution of these drugs. The 
objective of this study was to determine the brain permeation of ibuprofen and indomethacin 
by using constant in vivo infusion in rats. In addition, the effect of an efflux protein inhibitor 
probenecid and plasma protein binding on brain permeation of indomethacin was evaluated 
using the in vivo method and an in situ brain perfusion technique. Drug levels in plasma and 
brain tissue were measured by RP-HPLC after the plasma and the brain samples were purified 
by protein precipitation and solid phase extraction, respectively. In addition, protein-free 
plasma concentrations of indomethacin were determined after ultrafiltration of the plasma 
samples. Results indicate that after a 6-hour drug infusion, the brain to plasma ratio of 
ibuprofen was 0.02, and the corresponding ratio for indomethacin was 0.01. Co-
administration of probenecid increased total plasma, protein-free plasma and brain tissue 
concentrations, and the brain to plasma concentration ratio of indomethacin by 1.4-, 6.3-, 3.4, 
and 2.4-fold, respectively. The unidirectional brain uptake transfer constant (Kin) of 
indomethacin from buffer was 2.2 ± 0.2 x 10-3 ml/s/g (mean±SEM, n=3). Addition of 0.28 % 
or 2.8 % bovine serum albumin or probenecid into the perfusion fluid led to Kin values of 1.9 
± 0.3 x 10-3, 0.5 ± 0.1 x 10-3, and 3.7 ± 0.3 x 10-3 ml/s/g (mean±SEM, n=3-4), respectively. In 
conclusion, both ibuprofen and indomethacin permeated poorly into the rat brain after 
intravenous administration. Partly, this may be due to high plasma protein binding. However, 
a role for efflux systems at the blood-brain barrier cannot be ruled out because the brain 
permeation of indomethacin was increased by co-administration of the efflux inhibitor, 
probenecid.  
 
 
 
 
 
 
 
 
* Adapted with permission from:  
Anne Mannila, Jarkko Rautio, Marko Lehtonen, Tomi Järvinen, Jouko Savolainen: 
Inefficient central nervous system delivery limits the use of ibuprofen in neurodegenerative 
diseases. European Journal of Pharmaceutical Sciences 24: 101–105, 2005. Copyright 2004 
Elsevier BV 
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4.1 Introduction 
   The CNS is protected by the blood-brain barrier (BBB) and the blood-CSF barrier 
(BCSFB). These barriers allow compounds to enter the CNS from the blood circulation either 
via transcellular diffusion or via selective carrier-mediated transport mechanisms. In theory, 
the low permeation of a drug into the CNS can be attributed to several factors e.g. to its 
inadequate lipophilicity, unsuitable peripheral pharmacokinetics (e.g. high degree of plasma 
protein binding), or interactions with efflux transport systems at the BBB/BCSFB. In the case 
of ibuprofen and indomethacin, all of the above mentioned factors may affect their CNS 
permeation. Firstly, both ibuprofen and indomethacin are weak acids and almost completely 
ionized at the pH of 7.4. It is generally believed that only unionized molecules, being 
lipophilic enough, pass readily through the BBB/BCSFB by transcellular diffusion and 
therefore, ionization of ibuprofen and indomethacin in the circulation can limit the ability of 
these drugs to permeate the CNS. Secondly, both ibuprofen and indomethacin are highly 
protein bound in the systemic circulation (Bannwarth et al. 1990, Summerfield et al. 2006) 
which may limit their permeation into the CNS. Thirdly, both ibuprofen and indomethacin 
have been shown to interact with several transport proteins, including multidrug resistance-
associated proteins (MRPs) (Reid et al. 2003, Dallas et al. 2004), organic anion transporters 
(OATs) (Khamdang et al. 2002, Apiwattanakul et al. 1999), and organic anion transport 
polypeptides (OATPs) (Shitara et al. 2002). These transport protein families have been 
proposed to have a role as efflux transporters at the BBB/BCSFB (Zhang et al. 2004, Ohtsuki 
et al. 2002, Mori et al. 2004, Kusuhara and Sugiyama 2004, Kusuhara and Sugiyama 2005). 
 
   The CNS availability of ibuprofen and indomethacin is of interest because they may have 
clinically significant CNS actions in addition to their well-known peripheral anti-
inflammatory and analgesic effects. For example, there is a growing amount of 
epidemiological, in vitro and in vivo evidence that certain NSAIDs including ibuprofen and 
indomethacin may have AD modifying properties (Szekely et al. 2004, Etminan et al. 2003, 
Townsend and Pratico 2005, Gasparini et al. 2004). Before they can be recommended for 
long-term use in the prevention of AD there are, however, several points which need to be 
clarified. Obviously, more clinical evidence about their effects in AD prevention is needed. In 
addition, since the site of action is expected to be in the CNS, the rate and extent of CNS 
permeation by the NSAIDs are a crucial issues and furthermore, one must determine whether 
their CNS availability is high enough to achieve their disease modifying effects at therapeutic 
dosages. 
 
   The aim of this study was to determine the brain permeation of ibuprofen and indomethacin 
after intravenous infusion by calculating the total brain to plasma ratio under steady-state 
conditions. In addition, the brain permeation of indomethacin was studied also with the in situ 
brain perfusion technique. The effect of an efflux inhibitor probenecid on brain permeation of 
indomethacin was evaluated both after intravenous administration, and after in situ brain 
61 
 
perfusion by the simultaneous administration of indomethacin and probenecid. In addition, 
the effect of plasma protein binding on the brain permeation of indomethacin was evaluated 
using the in situ brain perfusion method. 
4.2 Experimental 
4.2.1 Materials 
   Indomethacin, ibuprofen sodium salt, probenecid and bovine serum albumin (BSA, 98 %) 
were purchased from Sigma-Aldrich (Steinheim, Germany). Ketamine (Ketaminol) and 
xylazine (Narcoxyl) were purchased from Intervet International B.V. (Boxmeer, The 
Netherlands), sodium chloride solution (0.9 %) from Orion Pharma (Espoo, Finland), and 
heparin (Heparin Leo) from Leo Pharma (Ballerup, Denmark). Solvents were of HPLC grade 
and all other reagents were of analytical grade. The water used in the experiments was 
ultrapure. 
4.2.2 Animals 
   Adult male Wistar rats weighing 250 (189-349) g (median with range) were purchased from 
the National Laboratory Animal Centre (Kuopio, Finland). Rats were housed in light- and 
temperature-controlled environment (12 hours light/dark cycle, 22 ± 1 °C). All experiments 
were carried out during the light phase. The rats had free access to tap water and food pellets. 
All procedures were reviewed and approved by the Animal Ethics Committee at the 
University of Kuopio. 
4.2.3 In situ brain perfusion in rats 
   Rats were anesthetized with ketamine (90 mg/kg, i.p.) and xylazine (8 mg/kg, i.p.). A small 
incision was made in the neck on the right side of the midline and the right carotid artery 
system was exposed. The right external carotid artery was ligated, and the right common 
carotid artery was cannulated with PE-50 catheters filled with 100 IE/ml heparin. The 
pterygopalatine artery was left open. Blood flow from the systemic circulation of the rats was 
stopped by severing the cardiac ventricles, and the perfusion fluid was infused via the 
common carotid artery at a rate of 10 ml/min using Harvard PHD 22/2000 syringe pump 
(Harvard Apparatus Inc., Holliston, MA, USA).  
 
   The perfusion fluid contained 150 µg/ml indomethacin (target dose) in Krebs-bicarbonate 
buffer (2.4 mM NaH2PO4, 4.2 mM KCl, 24.0 mM NaHCO3, 127.9 mM NaCl, 1.5 mM CaCl2, 
0.9 mM MgCl2) and it also contained 1 % (v/v) dimethyl sulfoxide resulting from the use of a 
stock solution of indomethacin in dimethyl sulfoxide. The perfusion fluid was gassed with 95 
% oxygen / 5 % carbon dioxide to pH 7.4, and 9 mM D-glucose was added to the solution. 
When the effect of probenecid and protein binding on indomethacin CNS permeation was 
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being studied, 240 µg/ml probenecid (target dose), 0.28 or 2.8 % (w/v) BSA were added to 
the solution. Prior to the perfusion, the perfusion fluid was filtered and heated to 37 °C. The 
perfusion procedure included a prewash for 30 s with indomethacin-free perfusion fluid, a 
perfusion with indomethacin for 30 s, and a wash period for 30 s with indomethacin-free 
perfusion fluid. When the effect of plasma protein binding was to be studied, BSA was 
perfused with indomethacin for 30 s. When the effect of probenecid was being investigated, 
also both washing periods included probenecid. 
4.2.4 In vivo infusion in rats 
   Rats were anesthetized with ketamine (90 mg/kg, i.p.) and xylazine (8 mg/kg, i.p.). Small 
incisions were made in the neck to the right side of midline and in the region of the left groin. 
The right jugular and the left femoral veins were exposed aseptically (Waynforth and 
Flecknell 1994), and cannulated with PE-50 catheters filled with 100 IE/ml heparin in order to 
collect blood samples and to infuse drug solutions, respectively. The catheters were 
exteriorised through a small incision made in the back of the neck. The rats were allowed to 
recover until the following day. 
 
   Ibuprofen (sodium salt) and indomethacin solutions were prepared in 0.9 % NaCl and 20 
mM phosphate buffered saline (pH 7.6), respectively, and filtered when necessary. Drug 
solutions were infused to conscious rats using a Univentor 864 syringe pump (Univentor Ltd., 
Zejtun, Malta). Ibuprofen (target dose 6 mg/kg/h) was infused for 2-6 hours, and 
indomethacin (target dose 7 mg/kg/h) was infused either in the absence of probenecid for 2-6 
hours, or in the presence of probenecid for 6 hours. Probenecid was administered as an 
intravenous loading dose of 99 mg/kg followed by infusion of 26.6 mg/kg/h in order to obtain 
steady-state concentrations (Deguchi et al. 1997).  
 
   Blood samples were withdrawn before and during the infusion. The drawn blood volume 
was substituted by 0.9 % NaCl. The blood samples were promptly centrifuged after 
withdrawal, and the obtained plasma was immediately frozen on dry ice. The blood in the 
cerebral capillaries was taken into account either by using a calculatory approach (I) or by 
perfusion the brain (II) as follows: at the end of the infusion, the rat was anesthetized and the 
thorax was opened. A needle was inserted into the left ventricle of the heart, and the brains 
were perfused with 0.1 M phosphate buffered saline (pH 7.4) for 6 min in order to obtain 
blood-free brain. The time required was obtained from a separate set of studies (data not 
shown). The rats were decapitated, and the brains were removed from the cranium, and 
immediately frozen on dry ice. 
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4.2.5 Analytical methods 
4.2.5.1 Sample preparation 
   Ibuprofen and indomethacin were isolated from the plasma samples by protein precipitation. 
Plasma (100 µl) was acidified with 50 µl of 1 M hydrochloric acid and vortexed for 5 
minutes. Acetonitrile (1.0 ml) was added and the samples were vortexed for 2 minutes, after 
which time the samples were centrifuged for 5 minutes (5500 g). The supernatants were 
collected, and the samples were evaporated to dryness under a nitrogen stream at 40 °C. Prior 
to analysis, the samples were reconstituted in 1.0 ml of 45 % (v/v) acetonitrile in water, 
filtrated and analysed by RP-HPLC.  
 
   Ibuprofen and indomethacin were isolated from the brain samples by protein precipitation 
and solid phase extraction (SPE). A complete hemisphere was homogenized to obtain 3.0 ml 
of homogenate. Indomethacin or ibuprofen was added as an internal standard, and the samples 
were acidified with 300 µl of 2 M hydrochloric acid and vortexed for 5 minutes. Acetonitrile 
(4.0 ml) was added, and the samples were vortexed for 2 minutes, after which time the 
samples were centrifuged for 10 minutes (7500 g), and the supernatants were collected. The 
supernatants were diluted with 2.0 ml of ultrapure water and applied to the preconditioned 
and equilibrated C18 SPE-cartridges (Discovery DSC-18; Supelco, Bellefonte, PA, USA). 
The cartridges were first washed with 2.0 ml of 1 % (v/v) acetic acid solution to maintain 
ibuprofen and indomethacin in the unionized form, and then washed with 2.0 ml of water. The 
analytes were eluted with 3.0 ml of acetonitrile, and evaporated to dryness under a nitrogen 
stream at 40 °C. Prior to analysis, plasma and brain samples were reconstituted in 400 µl of 
45 % (v/v) acetonitrile in water, filtrated and analysed by RP-HPLC.  
 
   The unbound fraction of indomethacin was determined from plasma samples obtained from 
the in vivo infusion studies and blank rat plasma spiked with indomethacin (160 µg/ml, n=3) 
and probenecid (390 µg/ml, n=3). In addition, the unbound fraction of indomethacin was 
determined from in situ perfusion fluid containing 0.28 or 2.8 % (w/v) of BSA. The plasma 
protein binding was determined by using the ultrafiltration method. Samples were applied to 
Centrifree® Micropartition Devices (Millipore Corporation, Bedford, MA, USA) and the 
protein-free fragment was obtained by centrifugation (1500 x g) for 15 minutes at 22 °C. The 
obtained ultrafiltrate was analysed by RP-HPLC.  
4.2.5.2 High performance liquid chromatography procedure 
   The apparatus (Merck LaChrom isocratic RP-HPLC system, Hitachi, Tokyo, Japan) 
consisted of a D-6000A interface, L-6200A intelligent pump, L-4500 diode array detector, 
AS-2000 autosampler, L-7350 column oven, D-7000 chromatography data station software 
(version 3.1) and a Zorbax SB-C18 (4.6 X 150 mm, 5 µm) analytical column (Agilent 
Technologies Inc., Little Falls, Wilmington, DE, USA). The mobile phase was a mixture of 
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20 mM phosphate buffer solution (pH 2.5) and acetonitrile (46:54 and 55:45 v/v, for plasma 
and brain samples, respectively). Ten µl of plasma samples, 30 µl of brain samples and 50 µl 
of protein-free plasma samples, were injected to the apparatus and detected at a wavelength of 
222 nm. 
 
   Ibuprofen: The calibration curves of the plasma and the brain methods were linear over a 
range of 0.2-50 µg/ml and 0.2-6 µg/ml, respectively. The precision of the plasma and the 
brain sample methods, were studied at a concentration level of the lower limit of 
quantification, and expressed as coefficients of variation (CV %); 4.6 % (n = 5) and 8.9 % (n 
= 4) for spiked samples containing 5 and 0.2 µg/ml of ibuprofen, respectively. The recovery 
was over 84 % with all studied methods. 
 
   Indomethacin: The plasma and brain assay procedures were linear over a range of 0.2-20 
µg/ml and 0.2-6 µg/ml, respectively. The accuracy, precision (coefficient of variation, %) and 
recovery of the brain method were determined at concentration levels of 0.5 µg/ml and 2.5 
µg/ml (n=3). Accuracy and recovery were 103-105 % and 77-79 %, respectively, and 
precision was 1.4 % at both concentrations. The precision and recovery of the plasma method 
were 2.1 % and 91 %, respectively, for spiked samples containing 4 µg/ml of indomethacin 
(n=6).    
 
   Ibuprofen and indomethacin concentrations in plasma were determined using external 
standards whereas the brain concentrations were assayed using an internal standard (ibuprofen 
for indomethacin and vice versa). 
4.2.6 Calculations 
   The results are expressed as mean ± standard error of mean (SEM) of 3-4 rats. Ibuprofen 
and indomethacin concentrations in plasma and brain tissue after intravenous infusion were 
dose-normalized. Ibuprofen levels in brain parenchyma were calculated by correcting the 
measured brain sample concentrations for the vascular space component, which was set at 2 
% (Morgan et al. 1992). Parenchymal brain concentrations of ibuprofen were calculated as 
follows: 
 
ppmi CVCC ×−=   (1) 
 
where Ci is the brain concentration (extracellular + intracellular), Cm is the drug concentration 
in the brain sample, Vp is the fraction of brain tissue space occupied by plasma, and Cp is the 
drug concentration in plasma. In the case of indomethacin, Ci equals Cm because the cerebral 
capillaries were washed clean of blood prior to decapitation. The specific gravity of brain 
tissue was assumed to be 1.0 (Ohno et al. 1978).  
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   The BBB transfer coefficient for unidirectional brain uptake (Kin) after in situ brain 
perfusion was calculated as follows (Smith and Allen 2003): 
 
pf
in CT
QK
×
=   (2) 
 
where Kin is the single point unidirectional transfer constant (ml/s/g brain), Q is the measured 
quantity of indomethacin in brain tissue (µg/g brain), T is the perfusion time (s), and Cpf is the 
perfusion fluid concentration of indomethacin (µg/ml).  
 
   The cerebrovascular permeability-surface area product (PA) after in situ brain perfusion for 
indomethacin from BSA-free perfusion fluid was calculated as follows (Smith and Allen 
2003): 
 





 −×−=
F
K1lnFPA in   (3) 
 
where PA is the cerebrovascular permeability-surface area product (ml/s/g brain) and F is the 
cerebral perfusion fluid flow (ml/s/g). F was experimentally determined in our laboratory 
from the brain uptake of diazepam and was 0.028 ml/s/g (1.68 ml/min/g) (Gynther et al. 
2008).  
 
   Data were analyzed by SPSS software (version 14.0). Independent samples t-test was used 
to examine the differences between the plasma and brain tissue concentrations and brain to 
plasma concentration ratios after 6-hours of infusion with indomethacin in the absence or 
presence of probenecid. One-way analysis of variance with Dunnett t-test was used to 
examine differences in Kin values after in situ perfusion between the groups. A p-value of 
0.05 was considered as the limit of statistical significance. 
4.3 Results 
4.3.1. Brain tissue and plasma concentrations after intravenous infusion 
   Ibuprofen and indomethacin concentrations in rat plasma and brain tissue were determined 
2, 3, 4 and 6 hours after the start of continuous intravenous infusion. Total plasma 
concentrations ranged from 31 to 45 µg/ml for ibuprofen, and from 80 to 151 µg/ml for 
indomethacin. The brain tissue concentration ranged from 0.46 to 0.71 for ibuprofen, and 
from 0.45 to 1.7 µg/g for indomethacin (Table 4.1). Brain penetration, determined as total 
brain to total plasma concentration ration, was found to be extremely low for both ibuprofen 
and indomethacin. Both drugs had brain to total plasma concentration ratios of less than 0.02 
(Table 4.1).  
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Table 4.1. Ibuprofen and indomethacin concentrations in rat plasma and brain tissue, and 
concentration ratios after constant infusion to freely moving rats (mean ± SEM, n=3). Drug 
concentrations are dose-normalized. IBU = ibuprofen target dose 6 mg/kg/h, IND = 
indomethacin target dose 7 mg/kg/h, IND + PROB = indomethacin target dose 7 mg/kg/h + 
probenecid target dose 99 mg/kg + 26.6 mg/kg/h. 
a = Calculated based on unbound fraction of 1.5% (Satterwhite and Boudinot 1991) 
b = n=2 
c = n=1 
d = Values are significantly different from 6-hours infusion with indomethacin (p<0.05; independent samples t-
test). 
 
   Our preliminary experiments with ibuprofen confirmed that the ibuprofen plasma steady-
state was reached within 6 hours (Figure 4.1). The time needed for ibuprofen to reach steady-
state in brain during intravenous infusion was not established by conducting preliminary 
experiments. Instead, it was decided to limit the infusion time to 6-hours based on the plasma 
concentration versus time profiles obtained in the preliminary experiments, and out of 
concern for the well-being of the animals. However, the results suggest that the brain 
ibuprofen concentrations were also at a steady-state after the 6 hour infusion (Figure 4.2). In 
contrast, it seemed that indomethacin steady-state was not achieved during the 6 hours of 
infusion since both the plasma and the brain concentrations increased with the passage of 
infusion time (Table 4.1). 
 
 
Treatment Sampling 
time 
Plasma concentration 
(µg/ml) 
Brain tissue 
concentration 
(µg/g) 
Mean brain to plasma 
concentration ratio 
  Total Protein-freea Total Total Protein-freea 
IBU 2 h 31 ± 9.2 0.47 0.46 ± 0.16 0.015 1.0 
 3 h  35 ± 9.7 0.53 0.53 ± 0.21 0.015 1.0 
 4 h 32 ± 2.5 0.48 0.69 ± 0.26 0.022 1.4 
 6 h 45 ± 1.6 0.68 0.71 ± 0.26 0.016 1.0 
IND 2 h 80 ± 7.4 0.21 ± 0.06b 0.45 ± 0.06 0.0057 2.0b 
 3 h 87 ± 5.8 0.17c 0.67 ± 0.10 0.0077 2.9c 
 4 h 131 ± 9.9 0.20 ± 0.05 1.2 ± 0.03 0.0095 7.4 
 6 h 151 ± 11 0.39 ± 0.10 1.7 ± 0.24 0.011 4.9 
IND + PROB 6 h 218 ± 9.4d 2.5 ± 0.12d 5.8 ± 0.7d 0.026d 2.6b 
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Figure 4.1. Individual plasma concentration versus time profiles of two rats during constant 
ibuprofen infusion at nominal dose of 6 mg/kg/h (○) and 1.2 mg/kg/h (●). 
 
 
 
Figure 4.2. Ibuprofen concentrations in rat brain tissue during constant infusion of 6 mg/kg/h 
(mean ± SEM). 
 
   Simultaneous administration of indomethacin and probenecid for 6 hours increased the 
plasma and brain tissue concentrations of indomethacin by 1.4-fold and by 3.4-fold, 
respectively. Co-administration of probenecid increased the indomethacin brain to plasma 
concentration ratio by 2.4-fold (Table 4.1, Figure 4.3.).  
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Figure 4.3. The effect of simultaneous probenecid administration on the plasma and brain 
tissue concentrations of indomethacin at 6 hours following continuous infusion of both 
compounds. IND = indomethacin target dose 7 mg/kg/h, IND + PROB = indomethacin target 
dose 7 mg/kg/h + probenecid target dose 99 mg/kg + 26.6 mg/kg/h. Data is presented as mean 
of 3 rats. 
4.3.2. Plasma protein binding of indomethacin 
   The plasma protein binding of indomethacin was studied in the absence and presence of an 
efflux inhibitor probenecid. It was noted that indomethacin was extensively bound to plasma 
proteins but probenecid decreased the protein binding of indomethacin. The unbound fraction 
of indomethacin in the absence and presence of probenecid in vitro was 0.9 ± 0.1 % and 2.3 ± 
0.3 % (mean±SD, n=3), respectively. The unbound fraction of indomethacin in plasma 
samples obtained after 6 hours of intravenous infusion was 0.2 % and 1.2 % in the absence 
and presence of probenecid, respectively (Table 4.1).  
 
   The unbound plasma concentration of indomethacin varied between 0.17 and 0.39 µg/ml 
after constant intravenous infusion (7 mg/kg/h) for 2-6 hours (Table 4.1). Co-administration 
of probenecid increased the unbound indomethacin concentration by 6.3-fold. 
4.3.3. The effect of albumin and probenecid on brain permeation of indomethacin after 
in situ brain perfusion 
   Brain permeation of indomethacin was determined in situ after 30 s perfusion. In the 
absence of albumin or probenecid, the Kin and the PA value of indomethacin was 2.2 ± 0.2 x 
10-3 ml/s/g brain and 2.3 x 10-3 ml/s/g brain, respectively. The addition of BSA into the 
perfusion fluid decreased the brain tissue concentration and Kin values of indomethacin 
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(Figure 4.3). The Kin value of indomethacin after perfusion with a perfusion fluid containing 
0.28 % and 2.8 % (w/v) BSA was 1.9 ± 0.3 x 10-3 and 0.5 ± 0.1 x 10-3 ml/s/g brain, 
respectively. The unbound fractions of indomethacin in the perfusion fluid containing 0.28 % 
and 2.8 % (w/v) BSA were 40 % and 4 %, respectively. 
 
   When the brains were perfused with a solution containing both indomethacin and the efflux 
inhibitor, probenecid, the brain tissue concentration and the Kin value of indomethacin were 
higher than after indomethacin administration alone (Figure 4.4). The Kin value of 
indomethacin in the presence of probenecid was 3.7 ± 0.3 x 10-3 ml/s/g brain. 
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Figure 4.4. The effect of BSA or probenecid on the brain tissue concentration (A) and Kin 
value (B) of indomethacin after in situ brain perfusion (target indomethacin concentration in 
perfusion fluid 150 µg/ml). Values are expressed as mean±SEM. *, values are significantly 
different from indomethacin (p<0.05; one-way analysis of variance with Dunnett t-test). 
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4.4 Discussion and conclusions 
   Ibuprofen and indomethacin permeated poorly into the rat CNS after intravenous 
administration, as indicated by the low total brain to total plasma concentration ratio of 0.02 
for ibuprofen and 0.011 for indomethacin. However, during the in situ brain perfusion, 
indomethacin entered the brain tissue quite readily with a PA value of 0.23 x 10-2 ml/s/g. A 
PA-value of 0.64 x 10-2 ml/s/g for indomethacin and 2.63 x 10-2 ml/s/g for ibuprofen  has been 
reported in a previous study (Parepally et al. 2006). For comparison, a brain uptake of 2.8 x 
10-2 ml/s/g has been determined for diazepam in our laboratory (Gynther et al. 2008). 
Diazepam permeates the brain rapidly and has even been used for the determination of the 
cerebral blood flow. Generally, if the compound has a PA-value that is much smaller than that 
of diazepam, it suggests that the brain uptake of the compound is being determined by factors 
other than the cerebral blood flow. 
 
   Ibuprofen levels in brain parenchyma were calculated by correcting the measured brain 
sample concentration for the cerebral vascular space component. The vascular space 
parameter is believed to have a value between 1 and 4 %, depending upon the method used 
(Preston et al. 1983). In the present study, a value of 2 % was adopted from the study by 
Morgan et al. (1992). The estimation of the vascular space component is critical for the 
quantification of drug concentration in brain tissue, especially when the concentration of the 
drug in plasma is high relative to that in brain parenchyma. In the case of ibuprofen, the 
calculations of brain parenhyma concentrations after 6-hours infusion using the vascular 
space value of 4 %, results in negative value in two rats out of three. This could suggest that 
ibuprofen does not enter the brain tissue at all, and the brain concentrations measured result 
only from ibuprofen present in the brain vasculature. However, it can also suggest that the 
contribution of the vascular component is overestimated, and the calculated brain parenchyma 
concentration is negative due to the relatively high plasma concentration. If one calculates the 
brain parenchyma concentration of ibuprofen using a vascular space value of 1 %, the brain 
concentrations of ibuprofen will be slighly higher, resulting in a brain to plasma ratio of 0.026 
in comparison to 0.016 obtained in the present study. This suggests that inaccuracies in the 
estimation of the vascular space value do not alter the main conclusion that ibuprofen is 
extremely poorly delivered to the brain. When the brain parenchyma concentrations of 
indomethacin were calculated using the vascular correction, the concentrations were negative 
resulting from relatively high plama concentrations of indomethacin. That is why the 
indomethacin levels in brain parenchyma were determined from brain tissue that was perfused 
free from blood thus eliminating the vascular component. The perfusion was conducted 
immediately after the experiment by inserting a needle into the left ventricle of the heart 
followed by a 6-minute perfusion with phosphate buffer. After this perfusion procedure, there 
was no need to correct the measured brain tissue concentration for the cerebral vascular space 
component. Therefore, inaccuracy in the estimation of the vascular space component has no 
impact on the determined brain levels of indomethacin.  
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   It is possible that the poor brain penetration of ibuprofen and indomethacin is due to efflux 
mechanisms expressed at the BBB/BCSFB. Several studies have reported that ibuprofen and 
indomethacin can interact with transporters suggested to have a role as efflux transporters at 
the BBB/BCSFB.  These transporters include MRP1, 4 and 5 (Reid et al. 2003, Dallas et al. 
2004), OAT1 and 3 (Khamdang et al. 2002, Apiwattanakul et al. 1999), and oatp1a1 and 1a4 
(Shitara et al. 2002).  
 
   The effect of efflux transporters on the brain permeation of compounds can be evaluated in 
vivo in several ways. One of the most sophisticated approaches is to use transgenic animals 
which lack a specific efflux transporter. Currently, at least an mdr1a/1b knockout (i.e. P-gp 
deficient) mouse model and an mrp2-deficient rat model are available. Another approach 
includes the use of an efflux inhibitor. If the brain to plasma ratio of a compound is increased 
in the presence of the inhibitor, this can be interpreted as evidence for involvement of an 
efflux mechanism (Golden and Pollack 2003). In addition, the in situ brain perfusion 
technique can be used to evaluate the effect of efflux mechanisms by adding an efflux 
inhibitor to the perfusion fluid (Chikhale et al. 1995, Cisternino et al. 2003). In the present 
study, both in vivo and in situ methods were used to evaluate whether the brain permeation of 
indomethacin could be increased by co-administration of an efflux inhbitor. Probenecid, a 
rather non-specific inhibitor of several efflux proteins expressed at the BBB was used. It is 
known that probenecid interacts with many efflux proteins e.g. MRP, OAT, OCT and MCT 
transport systems (Deguchi et al. 1997, Dallas et al. 2004). Therefore, if one assumes that 
indomethacin is a substrate of a probenecid-sensitive efflux system, then the CNS permeation 
of indomethacin should be enhanced by concurrent administration of probenecid. According 
to the in vivo infusion studies, the brain permeation of indomethacin seems to be increased by 
co-administration with probenecid as the brain to plasma concentration ratio of indomethacin 
was increased by 2.4-fold when indomethacin was infused in conjunction with probenecid. In 
order to validate this assumption, an additional experiment where the steady-state conditions 
of indomethacin both in plasma and in brain tissue have been established would be required. 
Importantly, the steady-state levels of indomethacin would have to be established also in the 
presence of probenecid as it is likely that probenecid increases the time where the steady-state 
of indomethacin is reached. In addition to the in vivo infusion studies, the in situ experiments 
suggest that probenecid is able to increase the initial brain uptake of indomethacin from BSA-
free perfusion fluid to some extent. This suggests that brain permeation of indomethacin may 
be influenced by a probenecid-sensitive efflux mechanism. The more precise identification of 
the efflux transporter possibly involved in the brain permeation of indomethacin cannot be 
established because probenecid, like many other commonly used efflux inhibitors, interacts 
with many different transport proteins. The effect of probenecid on the brain permeation of 
ibuprofen was also evaluated using the in vivo infusion method but our preliminary studies 
have suggested that probenecid has no effect on the brain permeation of ibuprofen 
(unpublished data).  
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   In vivo infusion studies suggest that the brain permeation of indomethacin can be increased 
by co-administration of probenecid since the brain to plasma concentration ratio of 
indomethacin was increased by 2.4-fold when indomethacin was infused in conjunction with 
probenecid. In addition to the increase in the brain concentration of indomethacin, probenecid 
affected also the peripheral pharmacokinetics of indomethacin as reflected by the elevated 
indomethacin plasma levels. In particular, the 6.3-fold increase in the unbound concentration 
of indomethacin is noteworthy.  Within the probenecid plasma concentration range used in the 
present study, probenecid is more than 60% bound to plasma proteins (Emanuelsson and 
Paalzow 1988). Therefore, probenecid may displace indomethacin from plasma proteins to 
some extent and thus increase the unbound plasma concentration of indomethacin. It is 
generally believed that only the unbound fraction of a drug is able to pass through the 
BBB/BCSFB. Therefore, it is possible that the increased brain to plasma concentration ratio 
of indomethacin after co-administration of probenecid is due to an increase in the unbound 
concentration of indomethacin in plasma.  
 
   The effect of plasma protein binding on brain permeation of indomethacin was further 
evaluated using the in situ brain perfusion method. The brain perfusion studies showed that in 
the absence of albumin, indomethacin entered the brain tissue with a Kin value of 2.2 x 10-3 
ml/s/g. After brain perfusion with buffer containing 2.8 % (w/v) BSA, a Kin value of 0.5 x 10-
3 ml/s/g was determined. The decrease in the brain uptake of indomethacin in the presence of 
albumin observed in the present and in a previous study (Parepally et al. 2006) is evidence 
that plasma protein binding plays a crucial role in brain permeation of indomethacin. In the 
study by Parepally et al., the role of plasma protein binding was also determined in the brain 
uptake of ibuprofen and another NSAID, flurbiprofen. With both compounds, a pronounced 
decrease in the brain uptake was observed when albumin was added to the perfusion fluid 
demonstrating that the brain permeation of these compounds is limited by plasma protein 
binding. 
 
   As discussed above, according to the in situ brain perfusion studies, the increase in unbound 
fraction enhances the brain permeation of indomethacin. The in vivo infusion experiments in 
the present study point in the same direction, i.e. the brain permeation of indomethacin was 
increased after there was an increase in the unbound fraction with the co-administration of 
probenecid. However, there are also opposite results to be found in the literature concerning 
the role of unbound drug concentration on the CNS permeation of NSAIDs. In the study of 
Matoga et al. (2002), ketoprofen was injected intraperitoneally to rats in either a 
carboxymethylcellulose solution or nanocapsule suspension. Despite the increase in the 
unbound fraction achieved with the latter formulation, there was no difference between the 
AUCCSF / AUCplasma ratios of ketoprofen after administration of these two formulations.  
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   In conclusion, less than 1-2% of the total plasma concentrations of ibuprofen and 
indomethacin can be found in the brain parenchyma following intravenous infusion to rats, 
suggesting that ibuprofen and indomethacin permeates poorly into the rat brain following 
systemic administration. Simultaneous administration of the efflux protein inhibitor, 
probenecid, was able to increase the brain permeation of indomethacin. However, probenecid 
affected also the peripheral pharmacokinetics of indomethacin since both the total and 
unbound plasma concentrations were increased. The increase in the unbound fraction after co-
administration of probenecid may account for the enhanced brain permeation of indomethacin 
after intravenous administration. This hypothesis is supported by the results from brain 
perfusion studies where it was observed that binding to BSA reduced the initial brain 
permeation of indomethacin. However, an effect on efflux systems at the BBB cannot be 
excluded as co-administration of probenecid slightly increased the initial brain uptake of 
indomethacin from protein-free perfusate. If one considers this result in terms of Alzheimer's 
disease prevention, then it does seem that the brain permeation of ibuprofen and indomethacin 
may not be large enough, because high plasma concentrations may be required in order to 
ensure adequate brain concentrations. However, from the adverse effect point of view, 
exposure to high doses of indomethacin would be most undesirable.  
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5 CSF PERMEATION OF KETOPROFEN AND INDOMETHACIN IN CHILDREN* 
Abstract. The objective of this study was to evaluate the cerebrospinal fluid (CSF) 
permeation of ketoprofen and indomethacin in healthy children. The participants (age 4-144 
months) received either ketoprofen (1 mg/kg) or indomethacin (0.35 mg/kg) intravenously 
prior to surgery under spinal anaesthesia. A single CSF and plasma sample from each 
individual was collected 7-67 minutes after the ketoprofen infusion, and 14-225 minutes after 
the indomethacin infusion. Drug concentrations were determined from the CSF, plasma and 
protein-free plasma using GC-MS. Total plasma, protein-free plasma and CSF concentrations 
of ketoprofen varied between 1700-9500 ng/ml (median 5800 ng/ml), 6.2-97 ng/ml (median 
35 ng/ml) and 1.4-24 ng/ml (median 6.6 ng/ml), respectively. Total plasma, protein-free 
plasma and CSF concentrations of indomethacin was in the range 90-2200 ng/ml (median 780 
ng/ml), 0.3-0.8 ng/ml (median 0.5 ng/ml) and 0.2-5.0 ng/ml (median 1.4 ng/ml), respectively. 
The CSF to plasma concentration ratio of both drugs remained below 0.01. In conclusion, 
both ketoprofen and indomethacin did permeate into the CSF of children after intravenous 
administration which may lead to both desired and adverse CNS effects of these drugs.  
 
 
 
 
 
 
 
 
 
 
 
 
 
* Adapted with permission from: 
Anne Mannila, Hannu Kokki, Marja Heikkinen, Merja Laisalmi, Marko Lehtonen, Hanna-
Leena Louhisto, Tomi Järvinen, Jouko Savolainen: Cerebrospinal fluid distribution of 
ketoprofen after intravenous administration in young children. Clinical Pharmacokinetics 45: 
737-743, 2006. Copyright 2006 Adis Data Information BV 
      
Anne Mannila, Elina Kumpulainen, Marko Lehtonen, Marja Heikkinen, Merja Laisalmi, Terhi 
Salo, Jarkko Rautio, Jouko Savolainen, Hannu Kokki: Plasma and cerebrospinal fluid 
concentrations of indomethacin in children after intravenous administration. Journal of 
Clinical Pharmacology 47: 94-100, 2007. Copyright 2007 the American College of Clinical 
Pharmacology 
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5.1 Introduction  
   Ketoprofen and indomethacin are traditional non-steroidal anti-inflammatory drugs 
(NSAIDs). They have analgesic, anti-inflammatory and antipyretic properties, which are 
thought to result mainly from peripheral inhibition of the cyclooxygenase (COX) enzyme at 
the site of tissue damage. In children, they are used for the treatment of inflammation and pain 
resulting from rheumatic and orthopaedic diseases and surgery (Maunuksela et al. 1988). In 
addition, indomethacin is the most commonly used pharmacological agent for the closure of 
the patent ductus arteriosus in preterm infants (Van Overmeire and Chemtob 2005). 
 
   In addition to peripheral sites of action, ketoprofen and indomethacin act also at the central 
level (Ossipov et al. 2000, Malmberg and Yaksh 1992, Daher and Tonussi 2003),  
prostaglandin E2 receptors being the key signalling elements where the spinal inflammatory 
hyperalgesia is inhibited (Reinold et al. 2005). In order to have central effects, a drug has to 
pass the blood-brain barrier and/or the blood-cerebrospinal fluid (CSF) barrier, which separate 
circulating blood from the brain and the CSF, respectively. These barriers efficiently control 
the exchange of substances between blood and the central nervous system (CNS). In 
principle, a drug molecule has to be small and lipophilic enough or a substrate for a transport 
protein located at the blood-brain/CSF barrier to be able to pass into the CNS. The CNS 
distribution of the NSAIDs (including ketoprofen and indomethacin) is largely unknown. 
Since there are CNS adverse effects such as dizziness, vertigo, headache, agitation and even 
psychosis and depression (Clunie et al. 2003, Tharumaratnam et al. 2000, Hoppmann et al. 
1991) often associated with the use of indomethacin, it has been suggested that indomethacin 
can penetrate into the CNS quite readily. However, determination of drug concentration in the 
CNS is required to validate this assumption.  
 
   There are few studies describing the CSF permeation of ketoprofen and indomethacin in 
adults. Netter et al. (1985) have shown that ketoprofen is able to pass the blood-CSF barrier in 
adults, since it was detected in the CSF between 15 minutes and 13 hours after intramuscular 
administration. The CSF concentrations of indomethacin have been studied in adults by 
Dittrich et al. (1984) and Bannwarth et al. (1990). Though Dittrich and co-workers could not 
detect indomethacin in the CSF, probably due to their insensitive analytical method, 
Bannwarth and co-workers demonstrated that indomethacin is able to enter the CSF. At 
present, there has been only one attempt to evaluate the CNS pharmacokinetics of ketoprofen 
in children (Kokki et al. 2002). In that study, the insensitivity of the analytical method 
permitted the detection of ketoprofen in only one CSF sample. The patient's ketoprofen 
concentrations in the CSF and plasma after 30 minutes of oral administration were 0.06 and 
7.4 µg/ml, respectively. This led to only limited information on CNS pharmacokinetics of 
ketoprofen in children, but did suggest that ketoprofen may be able to enter the CSF of 
children. We are unaware of any reports concerning the CSF permeation of indomethacin in 
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children. Consequently, more information is needed to clarify the CSF distribution of 
ketoprofen and indomethacin in children.  
 
   In the present study, the CSF distribution of ketoprofen and indomethacin was evaluated in 
children, aged 4-144 months. Children were given ketoprofen or indomethacin intravenously 
prior to surgery with spinal anaesthesia. Simultaneous venous blood and CSF samples were 
collected once from each patient. Samples were collected 7-67 minutes after ketoprofen 
administration and 14-225 minutes after indomethacin administration. Drug concentrations 
were determined in CSF, plasma and protein free plasma samples, and the concentration ratio 
between CSF and plasma was calculated in order to evaluate the CSF permeation. 
5.2 Experimental  
5.2.1 Materials 
   Ketoprofen (Orudis 50 mg/ml, Aventis Pharma S.A., Alcorcon, Spain) and indomethacin 
(Confortid 50 mg/ml: Alpharma, Copenhagen, Denmark) were used in the clinical studies. 
Ketoprofen, indomethacin, flurbiprofen and diclofenac used in the analytical studies were 
purchased from Sigma-Aldrich (Steinheim, Germany). All reagents used in the studies were 
of analytical grade, and the water was ultrapure. 
5.2.2 Clinical protocol 
   The studies were open and prospective and they were conducted in the Kuopio University 
Hospital, Finland. The protocols were approved by the Research Ethics Committee of the 
Hospital District of Northern Savo, and the Finnish National Agency for Medicines was 
notified. The trials were conducted in accordance with the Declaration of Helsinki. The 
parents, and children if old enough, were informed and the parents gave written informed 
consent and children provided assent.  
 
   The enrolled children were scheduled for lower abdominal, genito-urinary, orthopaedic 
surgery on the lower extremities and gastrointestinal surgery, all to be performed under spinal 
anaesthesia as day-case surgery. The exclusion criteria were contraindications for the drugs to 
be investigated or for spinal anaesthesia in their medical and surgical history and in a physical 
examination of vital signs. 
 
   The children received ketoprofen and indomethacin as a single intravenous infusion which 
lasted for 5-10 minutes. The blood and CSF samples were collected at pre-selected time 
points after the end of the drug infusion. One ml of CSF was collected at the induction of 
spinal analgesia. At the same time, a venous blood sample of 3 ml was collected into a 
heparinised tube via an indwelling catheter inserted into the contralateral forearm vein 
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compared to the vein used for the infusion. Plasma was obtained by centrifugation and the 
plasma and the CSF samples were protected from light and stored at -85 °C until analysis.  
 
   After the surgery, the children were transferred to the post-anaesthesia care unit for 
monitoring of vital signs, pain and all adverse effects (not classified as to whether considered 
as drug-related or not).  
 
   Ketoprofen: 24 children were asked to participate but the parents of two children refused to 
provide informed consent, and one child was withdrawn because insertion of an intravenous 
line was not successful. Hence the study population was 21 children. The children were 
sedated before spinal anaesthesia with thiopental sodium. 
 
   The children received ketoprofen at a dose of 1 mg/kg in 20 ml of normal saline. The blood 
and CSF samples were collected at 7 min to 67 min (median 23 min) after the end of the 
ketoprofen infusion.  
 
   Indomethacin: 32 children were asked to participate; the parents of one child refused to 
provide informed consent, hence leaving a group of 31 children for the study population. The 
children were premedicated with buccal midazolam (0.375 mg/kg up to 7.5 mg) and ketamine 
(1.25 mg/kg up to 25 mg) 15 - 30 min before anaesthesia. All children were sedated before 
spinal anaesthesia (n=26) or combined spinal-epidural anaesthesia (n=5). 
 
   The children received indomethacin at a dose of 0.35 mg/kg. The blood and CSF samples 
were collected at 14 min to 3 hours 45 min (median 58 min) after the end of the indomethacin 
infusion.  
5.2.3 Analytical methods 
5.2.3.1 Sample preparation 
   Ketoprofen and indomethacin concentrations in CSF, plasma and protein-free plasma were 
determined by GC-MS. Protein-free plasma was obtained by the ultrafiltration method; 
plasma was placed into Centrifree® ultrafiltration devices (Millipore, Bedford, MA, USA) and 
centrifuged for 15 minutes at 1500 g at 23 °C. A SPE method was developed for sample pre-
treatment. A method previously described by Leis et al. (1996) with modifications was used 
for sample derivatisation. 
 
   Ketoprofen: CSF (250 µl), protein-free plasma (75-100 µl), or plasma (100 µl) sample, 
containing the internal standard flurbiprofen, was acidified with 20 µl of 1 M hydrochloric 
acid, and applied into C-18 SPE-cartridges (Discovery®, DSC-18, 1ml/100mg, Supelco, 
Bellefonte, PA, USA). The cartridges were washed with 20 % (v/v) methanol (1.0 ml), and 
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ketoprofen and the internal standard were eluted with ethyl acetate (1.0 ml). After 
evaporation, 100 µl of pentafluorobenzylbromide (3.5 % v/v, in acetonitrile) and 20 µl of di-
isopropylethylamine were added to the samples. After one hour, the samples were extracted 
with water and toluene. In the case of the CSF and total plasma samples, the ketoprofen 
concentration was analysed from the toluene phase, whereas in the case of protein-free plasma 
samples, the samples were further derivatised. The toluene phase was evaporated to dryness 
and 50 µl of hydroxylamide hydrochloride (3 %, in pyridine) were added. After two hours at 
75 °C, the samples were extracted with water and hexane. The hexane phase was collected 
and evaporated, and then 50 µl of pyridine and 100 µl of bis(trimethylsilyl)trifluoracetamide 
were added to the residue. After 20 min in 75 °C, samples were evaporated, dissolved in 
toluene and analysed. 
 
   Indomethacin: CSF (250 µl), protein-free plasma (120-200 µl), or plasma (50-100 µl) 
sample, containing the internal standard diclofenac, was acidified and applied into C-18 SPE-
cartridges (Discovery®, DSC-18, 1ml/100mg, Supelco, Bellefonte, PA, USA). Cartridges 
were washed with 20 % (v/v) methanol (1.0 ml), and indomethacin and the internal standard 
were eluted with ethyl acetate (2.0 ml). After evaporation, 200 µl of 
pentafluorobenzylbromide (3.5 % v/v, in acetonitrile) and 50 µl of di-isopropylethylamine 
were added to samples. After two hours, the samples were extracted with water and toluene, 
and the toluene phase was analysed. 
5.2.3.2 Gas-chromatography mass-spectrometry procedure 
   GC-MS operating in the negative chemical ionisation was used for the determination of 
ketoprofen and indomethacin concentrations in CSF and plasma samples. The determinations 
were accomplished by the Agilent GC-NCI-MS system (6890 N gas chromatograph, 7683 
autosampler and 5973 N mass detector, Agilent Technologies, Palo Alto, CA, USA). Data 
were processed by the Agilent Enhanced Chemstation software (version c.00.01.08). A cross-
linked 5 % phenyl methyl siloxane capillary column (HP-5MS; 30 m x 0.25 mm x 0.25 µm, 
Agilent Technologies) was used with helium as the carrier gas (1.0-1.5 ml/min). Methane was 
used as the reagent gas.  
 
   Ketoprofen: The sample (1 µl for CSF and total plasma samples and 3 µl for protein-free 
plasma samples) was injected into the system in the pulsed splitless mode. The temperature 
program was as follows: 1 min at 90 °C, followed by an increase of 20 °C/min to 280 °C. 
Final temperature was held for 3.5 min. Selected ion monitoring at m/z 253 and 340 for 
ketoprofen pentafluorobenzylbromide ester and pentafluorobenzylbromide ester 
hydroxylamine-trimethylsilyl derivative, respectively, and 243 for flurbiprofen was used to 
quantify the compounds.  
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   Indomethacin: The sample (1 µl) was injected in the splitless mode. The temperature 
program was as follows: 1 min at 180 °C, followed by an increase of 20 °C/min to 300 °C. 
Final temperature was held for 7 min. Selected ion monitoring at m/z 356 for indomethacin, 
and 294 for diclofenac was used to quantify the compounds. 
5.2.4 Statistics 
   Drug concentrations in the CSF and plasma (total and protein-free plasma) are presented for 
each individual along with median supplemented with range or average with standard 
deviation (SD), as appropriate.  The impact of administration time and the child's age on drug 
CSF concentration was tested using linear regression analysis. Mann-Whitney U-test was 
used to test if the indomethacin CSF concentration, child's age or administration time were 
associated with the observed CNS adverse effects. A p-value of 0.05 was considered as the 
limit of statistical significance. Data was analysed by SPSS software (version 11.5). 
5.3 Results 
5.3.1 Analytical methods 
   The methods for the determination of ketoprofen concentration from human CSF and 
plasma (total and protein-free concentration) were partially validated with regard to linearity, 
accuracy and precision. The range of the method was 0.4-40, 1000-30000 and 1-100 ng/ml for 
CSF, total plasma and protein-free plasma samples, respectively.  
 
   The accuracy and intra-day precision of the methods for the determination of indomethacin 
concentration from human CSF and plasma (total and protein-free concentration) and 
recovery from human plasma were studied in the following concentrations: 0.2, 3/4, and 
16/20 ng/ml for CSF/plasma ultrafiltrate method, and 90 and 150 ng/ml for plasma method. 
The accuracy and recovery of the methods were in the ranges 98-122 % and 85-87 %, 
respectively. The intra-day precision (% RSD, n=3) of the methods was 34 %, 15 %, 6 %, 7 % 
and 3 % at concentrations of 0.2, 3/4, 16/20, 90 and 150 ng/ml, respectively. CSF and plasma 
ultrafiltrate methods were linear over the concentrations of 0.2-20 ng/ml and the plasma 
method over the concentrations of 90-3000 ng/ml. 
5.3.2 CSF and plasma concentrations 
   The drug concentrations in CSF, plasma and protein-free plasma analysed from each patient 
are presented in Tables 5.1 and 5.2. Ketoprofen was detected in each CSF sample, whereas in 
two indomethacin samples, the drug concentration in the CSF was below the limit of 
quantitation. In addition, two indomethacin CSF samples were excluded from analysis due to 
blood contamination.  
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   The ketoprofen concentration in the CSF ranged from 1.4 to 24 ng/ml (median 6.6 ng/ml) 
after the dose of 1 mg/kg. The indomethacin concentrations in the CSF were in the range from 
0.2 to 5.0 ng/ml (median 1.4 ng/ml) after the dose of 0.35 mg/kg. The impact of time to CSF 
concentrations was tested using linear regression analysis. CSF concentrations of ketoprofen 
increased statistically significantly with increasing time (p = 0.026). There was no correlation 
between indomethacin CSF concentration and the time from indomethacin administration 
(Figure 5.1). 
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Figure 5.1. Total plasma (■), protein -free plasma (○) and CSF (●) concentrations of 
ketoprofen (A) and indomethacin (B) after intravenous administration in all patients.  
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Table 5.1. Ketoprofen concentrations in the CSF and plasma (total and protein-free plasma 
concentration). The study population included 13 males and 8 females, aged 13-94 (43) 
months, weighing 8-33 (14) kg (range with median). 
Sampling 
time  
(min) 
Concentration 
(ng/ml) 
Age  
(mo) 
CSF Plasma, 
protein-free 
Plasma, total 
7 1.4 48 7514 18 
11 14.0 97 9459 55 
15 2.3 35 6717 43 
16 7.3 63 9422 13 
17 6.6 58 7436 74 
18 4.7 46 5866 25 
18 1.8 28 5757 79 
19 3.5 26 4752 86 
19 2.5 30 6643 78 
21 6.0 66 5388 39 
23 3.6 51 6900 25 
26 14.4 52 5406 28 
29 5.3 31 6111 94 
36 7.5 44 3100 13 
44 7.9 10 2959 91 
49 24.0 56 7745 15 
49 3.8 6.2 2125 73 
56 9.4 15 2954 25 
58 12.5 8.8 2411 41 
58 7.0 7.9 1654 64 
67 13.8 18 2461 65 
Mean 7.6 38 5370 50 
SD 5.5 23 2378 28 
Range 1.4-24 6.2-97 1654-9459 13-94 
Median 6.6 35 5757 43 
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Table 5.2. Indomethacin concentrations in the CSF and plasma (total and protein-free plasma 
concentration), and observed CNS adverse effects for each individual. 
Sampling 
time  
(min) 
Concentration 
(ng/ml) 
Gender Age (mo) Height 
(cm) 
Weight 
(kg) 
CSF Plasma, 
protein-free 
Plasma, 
total 
14 bq 0.8 2200 M 121 135 33 
14 1.2 0.6 2200 M a 14 76 11 
15 c 0.6 1700 M a 20 84 11 
17 2.6 0.5 1400 F 82 115 18 
19 bq 0.5 1300 M 115 120 28 
20 3.8 0.8 1700 M 19 82 11 
20 4.7 0.6 2200 M 6 66 7 
26 1.2 0.5 1200 M 22 80 12 
28 0.7 0.7 1800 M 51 101 17 
30 1.9 0.5 1600 F a 31 89 12 
36 0.8 0.4 200 M a 19 82 11 
36 0.2 0.5 1600 M 64 120 19 
36 0.5 0.5 1100 F 107 140 28 
40 2.1 0.7 1700 M a 70 120 22 
50 1.0 0.3 620 M 45 98 15 
58 0.5 0.6 1300 M 107 124 22 
66 1.0 0.4 660 F 37 89 13 
72 2.1 0.5 1000 F 18 84 11 
75 4.4 0.3 650 M 25 89 12 
75 2.4 0.3 510 M 31 91 10 
77 1.4 0.6 780 M 72 119 21 
85 2.6 0.4 750 F 25 89 12 
92 5.0 0.4 520 M 16 75 10 
105 1.4 0.3 330 F 116 128 23 
106 1.2 0.3 440 M 69 110 20 
134 2.5 0.3 260 M 117 152 45 
174 0.2 0.3 130 M 96 123 20 
 
Continues on the next page... 
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Table 5.2. continued… 
Sampling 
time  
(min) 
Concentration 
(ng/ml) 
Gender Age (mo) Height 
(cm) 
Weight 
(kg) 
CSF Plasma, 
protein-free 
Plasma, 
total 
180 3.0 0.3 350 M 4 63 7 
184 1.3 0.3 160 F 15 82 13 
200 c 0.3 90 M 94 123 24 
225 2.0 0.3 250 M 144 165 48 
Mean 1.9 0.5 990 - 57 104 18 
SD 1.3 0.2 670 - 42 26 10 
Range ≤ 5.0 0.3-0.8 90-2200 - 4-144 63-165 7-48 
Median 1.4 0.5 780 - 45 98 15 
a. CNS adverse effect (agitation) 
bq = below quantitation limit; c = sample contaminated; F = female; M = male 
 
 
   The ketoprofen plasma concentrations ranged from 1700 to 9500 ng/ml (median 5800 
ng/ml). Total plasma concentrations of indomethacin ranged from 90 to 2200 ng/ml (median 
780 ng/ml). The CSF to plasma concentration ratio of both ketoprofen and indomethacin 
remained less than 0.01 at all times (Figure 5.2). The concentration ratio of ketoprofen ranged 
from 0.0002 to 0.006 (median 0.001) and the concentration ratio of indomethacin from 0.0001 
to 0.001 (median 0.002).  
    
 
 
Figure 5.2. CSF to total plasma concentration ratio of ketoprofen (●) and indomethacin (○) 
from each patient.  
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Figure 5.3. CSF to protein-free plasma concentration ratio of ketoprofen (●) and 
indomethacin (○) from each patient.  
 
   Both ketoprofen and indomethacin were extensively bound to plasma proteins. The 
unbound fraction of ketoprofen ranged from 0.003 to 0.01 (median 0.006) and was 
independent of the plasma concentration within the measured concentrations of 1.7 - 9.5 
µg/ml. The unbound fraction of indomethacin in plasma ranged from 0.0003 to 0.004 (median 
0.0005). The CSF to protein-free plasma ratio of ketoprofen approached unity, but 
equilibrium between CSF and protein-free plasma samples was not reached within the 67 
minute study period. Indomethacin concentrations were higher in the CSF than in protein-free 
plasma; only three children had a higher indomethacin concentration in protein-free plasma 
than in the CSF (Figure 5.3). 
 
   There was a correlation between the CSF indomethacin concentration and the child's age, 
younger children having higher CSF concentrations than older ones (p=0.038) (Figure 5.4). 
No such correlation was found between the CSF concentration of ketoprofen and the age of 
the children. 
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Figure 5.4. CSF concentrations of indomethacin in children aged 4-144 months.  
5.3.3 Observed adverse effects 
   No serious adverse events were reported in the present study. In the ketoprofen study, five 
children reported mild pain at the injection sites. In the indomethacin study, the observed 
adverse effects were analysed in more detail; eleven children developed 12 non-serious 
adverse effects. Five children were agitated, three children vomited, one child experienced 
nausea, two children had abdominal pain and one child developed shivering. The observed 
agitation was not associated with the indomethacin CSF concentration or age. Agitation was 
associated with administration time (p=0.032) and occurred among children who had received 
indomethacin within 40 minutes prior to CSF sampling.    
5.4 Discussion and conclusions 
   The determination of the CSF permeation of ketoprofen and indomethacin is important, 
because it has been proposed that the antinociceptive effects of NSAIDs could partly be due 
to central effects of these drugs (Reinold et al. 2005). In order to act centrally, a sufficient 
amount of the drug must enter the CNS. In the present study, the CSF permeation of 
ketoprofen and indomethacin was studied in children after intravenous administration of these 
drugs. The analytical methods used were sensitive enough to allow the determination of 
ketoprofen and indomethacin in the CSF, and it was shown that both ketoprofen and 
indomethacin are able to enter the CSF after intravenous administration. However, the CSF 
permeation of these two NSAIDs was limited; less than 1% of the drug plasma concentration 
was found in the CSF. The median lumbar CSF concentrations were 6.6 ng/ml for ketoprofen 
and 1.4 ng /ml for indomethacin. Whether these concentrations present in the lumbar CSF are 
clinically relevant will have to be evaluated in further studies. In behavioural studies in rats, 
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1.9 nmol (= 680 ng) of indomethacin injected intrathecally was required to produce 50% 
inhibition of the control response (Malmberg and Yaksh 1992).  
 
   In the studies where ketoprofen and indomethacin concentrations were measured in adults 
after intramuscular administration, the CSF to plasma concentration ratios were fairly similar 
to those obtained in the present study (Netter et al. 1985, Bannwarth et al. 1990). This 
suggests that the CSF permeation of ketoprofen and indomethacin in children is comparable 
to that of adults. In the present study, younger children appeared to have higher CSF 
indomethacin concentrations than older children. Although the validity of this finding must be 
confirmed by further experiments, it raises the possibility that the CNS permeability of 
indomethacin in children may be affected by age. On the contrary, no indication of any age-
related CSF permeation was found for ketoprofen. However, it cannot be excluded that the 
age range (13-94 months) was too small to reveal any age-related effects. In general, few 
studies have described the effect of age on CNS permeability of different compounds. 
According to one study where age-related changes in the plasma to CSF equilibration half-life 
of acetaminophen were investigated, the BBB permeability did not seem to be increased in 
early infancy (van der Marel et al. 2003). However, more research information is needed in 
the area of CNS transport of drugs in children. In addition to age-dependency in BBB 
permeability, age-dependency in plasma protein binding might also explain the increased CSF 
distribution of indomethacin in younger children compared to older children. The serum 
concentration of albumin is lower in infants of at least up to 6 months of age than in adults 
(Kanakoudi et al. 1995), and therefore higher unbound fractions of compounds that bind to 
albumin can be observed in young children compared to older children or adults (Herngren et 
al. 1991). Higher unbound concentrations of compounds whose CNS distribution is restricted 
by plasma protein binding could increase their CNS delivery. In the present study, it could not 
be demonstrated that the unbound fraction of indomethacin was dependent on the child’s age 
suggesting that age-dependency in plasma protein binding does not explain the observed age-
dependency in the CSF concentrations of indomethacin.   
 
   In the present study, the CSF concentrations of ketoprofen and indomethacin were 
determined from the lumbar space. The drug concentrations in the lumbar CSF space are 
therapeutically relevant, because NSAIDs can reduce hyperalgesia by inhibiting the 
production of PGE2 in the spinal cord. Furthermore, the nerves conducting noxious 
information from the lower part of body enter into the spinal cord at the same level. However, 
it has to be remembered that the lumbar concentration of the drug is not indicative of CNS 
permeation and disposition of the drug as a whole. Firstly, there are remarkable differences in 
drug concentrations between ventricular and spinal CSF, probably because of the exchange of 
drugs between the CSF and the cord tissue bordering the spinal subarachnoid space (Shen et 
al. 2004). Moreover, the CSF and brain parenchyma are considered to be two separate 
compartments e.g. due to differences between the BBB and BCSFB. Therefore, the drug 
concentrations determined in the present study represent only the lumbar distribution of 
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ketoprofen and indomethacin, and not the overall distribution to the CSF, not to mention the 
brain tissue distribution of these drugs. 
 
   The use of indomethacin is often associated with CNS adverse effects, such as dizziness, 
vertigo, headache, agitation, and even psychosis and depression (Tharumaratnam et al. 2000, 
Hoppmann et al. 1991, Clunie et al. 2003). In the present study, five out of the 31 children 
were agitated in the recovery room. Agitation is common in children after inhalation 
anaesthesia (Johr 2002), but it is rarely reported after spinal anaesthesia (Kokki and Hendolin 
1995). Therefore, the observed agitation could have been an indomethacin-related CNS 
adverse effect (Clunie et al. 2003). However, in the present study the reported adverse effects 
were not sub-classified as being either drug-related or not. The children who experienced 
agitation did not have higher CSF indomethacin concentrations than those without CNS 
adverse effects (Table 5.2). According to our present understanding, the connection between 
CSF concentrations of indomethacin and indomethacin-related CNS adverse effects is rather 
complicated. For instance, it is not clear whether the indomethacin-related CNS adverse 
effects are simply due to changes in cranial blood flow or whether indomethacin has also 
direct effects on central neurons. If the latter is true, then the CSF permeation of indomethacin 
may be of clinical relevance.    
 
   In the present study, the median CSF concentration of indomethacin was reached relatively 
rapidly, and the sampling times chosen did not detect the initial rise in the CSF concentrations 
of indomethacin (Figure 5.1). On the contrary, the CSF concentrations of ketoprofen 
increased with time. As both NSAIDs studied in the present study achieved CSF 
concentrations of approximately 1% of the plasma concentrations, it seems that these two 
NSAIDs have relatively similar extents but different rates of CSF entry, with indomethacin 
being able to pass across the BCSFB more readily than ketoprofen. Lipophilicity of a drug is 
one of the factors which affect its ability to pass through the BBB and the BCSFB, and to 
enter the CNS. At the pH of 7.4, the apparent logP values of indomethacin and ketoprofen are 
0.89 and -0.09, respectively (Austin et al. 2002). It can be hypothesized that because 
indomethacin is a more lipophilic molecule than ketoprofen, it enters the CSF more readily. 
 
   In studies where the antinociceptive activity of ketoprofen has been examined, it has been 
discovered that ketoprofen has a central analgesic effect, but rather high doses are needed to 
produce a reduction of nociceptive responses in electrophysiological experiments (Herrero et 
al. 1997). Gaitan et al. (2004) discovered that HCT-2037, a nitric oxide releasing derivative 
of S-ketoprofen, was more potent and effective as a centrally active antinociceptive agent than 
S-ketoprofen itself. It is interesting to observe that the introduction of the nitric oxide 
releasing group into the ketoprofen molecule makes the compound more lipophilic. The log P 
value of neutral ketoprofen molecule is 2.81 whereas that of HCT-2037 is 4.19 (calculated 
using ACD/Labs). As lipophilicity is an important factor determining the ability of a molecule 
to pass through the BBB and BCSFB, it is possible that the central antinociceptive actions of 
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HCT-2037 are improved at least partly because HCT-2037 may enter the CNS more readily 
than S-ketoprofen. However, other possibilities may explain the difference in the 
antinociceptive properties of HCT-2037 and in S-ketoprofen, e.g. different mechanism of 
action of HCT-2037 (Gaitan et al. 2004). In addition, a role for efflux mechanisms and altered 
interactions with efflux transporters cannot be excluded. 
 
   The BBB and the BCSFB, in addition to forming an anatomical barrier and allowing 
compounds to enter the CNS by passive diffusion only by the transcellular route, express 
various efflux transporters, with P-glycoprotein being probably the most well-known.  In 
addition, the MRPs, OATs and OATPs have been suggested to have a role as efflux 
transporters at the BBB and the BCSFB (Ohtsuki et al. 2002, Kusuhara and Sugiyama 2004, 
Mori et al. 2004, Zhang et al. 2004, Kusuhara and Sugiyama 2005). As both ketoprofen 
(Ohtsuki et al. 2002) and indomethacin (Reid et al. 2003, Dallas et al. 2004, Apiwattanakul et 
al. 1999, Khamdang et al. 2002, Shitara et al. 2002) have been shown to interact with these 
transport proteins, a role for efflux mechanisms cannot be excluded in the CNS permeation of 
these drugs. 
 
   In the systemic circulation, most NSAIDs are extensively bound to plasma proteins. In the 
present study, the unbound fraction of ketoprofen and indomethacin in plasma was less than 
1%, which is consistent with earlier reports (Netter et al. 1985, Bannwarth et al. 1990). The 
extensive protein binding of ketoprofen and indomethacin may restrict their permeation into 
the CNS, as it is believed that only unbound drug can pass through biological membranes 
(Rowland and Tozer 1995). Since the CSF space is rather difficult to access, the estimation of 
the CSF concentration of the drug based on the unbound plasma concentration would be 
advantageous. Netter et al. (1985) have reported that the CSF levels of ketoprofen were 
equivalent to the protein-free serum levels 2-3 hours after intramuscular administration. 
Unfortunately in the present study the study period of 67 minutes was too short to allow 
determination of reliable tmax and Cmax values in CSF, and further, to evaluate the possible 
equilibrium between the CSF and unbound plasma levels of ketoprofen. However, the CSF 
levels increased with time, resulting in unbound plasma to CSF ratio which approached unity. 
 
   In the case of indomethacin, drug concentrations were higher in the CSF than in protein-free 
plasma; only three children had a higher indomethacin concentration in protein-free plasma 
than in the CSF (Table 5.2). In the present study, the CSF was regarded as practically protein-
free, as the albumin concentration in the CSF is only 0.4% of that present in serum (Davson 
and Segal 1996). According to Muller et al. (1991), indomethacin binds to proteins present 
not only in the plasma but also in the CSF, the mean binding percentage of indomethacin 
being 40%. Therefore, as we only measured the total CSF concentration of indomethacin, it is 
possible that we observed higher indomethacin concentrations in the CSF than in protein-free 
plasma. Thus, it is important to determine the unbound drug concentration from the CSF, 
especially if the drug is extensively bound to proteins. There are some studies where total and 
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unbound CSF drug concentrations have been determined, for instance after propofol 
administration. While the unbound fraction of propofol in plasma was 1%, in the CSF the 
unbound fraction was 31% (Dawidowicz et al. 2003). Additionally, total CSF concentrations 
of propofol were much higher than the unbound plasma concentrations. Protein binding may 
have a notable influence on the drug CSF concentration, particularly when the CSF is 
sampled at the lumbar space, since the protein concentrations are higher in lumbar CSF than 
in ventricular or cisternal CSF (Shen et al. 2004). Given the possible contribution of protein 
binding within the (lumbar) CSF one has to be careful in making predictions of CSF 
concentrations based on unbound plasma concentrations. Other reasons that might explain 
higher CSF concentrations of a compound relative to plasma unbound concentrations can be 
active transport mechanisms at the BCSFB or differences in the pH of plasma versus CSF 
(Rowland and Tozer 1995). 
 
   In conclusion, the present study demonstrated that ketoprofen and indomethacin are able to 
permeate the CSF of children after intravenous administration. The determination of the CSF 
concentrations of ketoprofen and indomethacin was achieved with a sensitive GC-MS 
method. In terms of evaluating the extent of CSF permeation based on total plasma 
concentration, the CSF permeation of ketoprofen and indomethacin was rather limited after 
intravenous administration since less than 1% of the total plasma drug concentration was 
detected in the CSF. Whether this is sufficient to mediate any central antinociceptive effects 
in the lumbar space, or be involved in other central mechanisms of action remains to be 
clarified.  
 
   The extent of the CSF permeation of ketoprofen and indomethacin in children was rather 
similar to the CSF permeation of these drugs reported in adults. In the case of indomethacin, 
the present study suggests that CSF distribution may be affected by age as the younger 
children appeared to have higher indomethacin CSF concentrations than the older children.  
This finding, however, needs to be confirmed in future studies.  
 
   No equilibrium between the CSF concentrations and the unbound drug concentrations in the 
plasma was observed in the present study, suggesting that the unbound plasma concentration 
may not be indicative of the CSF concentration of ketoprofen and indomethacin. When the 
CSF concentration of ketoprofen was studied, the Cmax and tmax values could not be assessed 
with the study protocol used, but the CSF to unbound plasma concentration ratio approached 
unity. On the contrary, the CSF total concentrations of indomethacin were higher than those 
in protein-free plasma. This might be due to protein binding of indomethacin in the CSF and 
emphasizes the importance of the determination of unbound drug concentration from the CSF 
for those drugs that are highly bound to proteins.  
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6 GENERAL DISCUSSION 
   In modern CNS drug development it is becoming clear that one has to take into account 
several properties in order to have a successful compound. A good CNS drug needs to possess 
not only high permeability across the BBB but also low potential to be a substrate for active 
efflux mechanisms and appropriate partitioning of the unbound drug between blood and brain 
(Jeffrey and Summerfield 2007). Furthermore, one has to remember that the rate and extent of 
CNS distribution are separate processes and, for instance, a slow rate of transport across the 
blood-CNS barriers does not necessarily lead to a low level of drug in the CNS, and vice 
versa  (Hammarlund-Udenaes 2000). 
 
   The extent of CNS permeation is often quantified as the total brain to total plasma 
concentration ratio. However, there is a growing awareness that the total brain to total plasma 
concentration ratio, which is dependent upon several factors including protein binding in 
plasma and brain, BBB uptake, influx and efflux transport mechanisms, metabolism and bulk 
flow, is of limited value in the determination of CNS permeation. It has been suggested that 
the use of unbound drug concentrations both in plasma and in brain tissue or the use of BBB 
PA values could provide more accurate information about CNS permeation of compounds  
(Jeffrey and Summerfield 2007, Liu et al. 2005, Pardridge 2004).  
 
   The aim of the present study was to obtain a better understanding of the CNS permeation 
and distribution properties of three traditional NSAIDs ibuprofen, indomethacin and 
ketoprofen. It was hypothesized that their CNS permeation would be limited after systemic 
administration. The extent of the CNS permeation was evaluated based on the ratio between 
the total brain or the total CSF concentration and the plasma concentration. Indeed based on 
the low brain or CSF to plasma ratios determined in this study, it can be concluded that the 
CNS permeation of ibuprofen, indomethacin and ketoprofen is limited. Furthermore, it is 
suggested that the CNS permeation of indomethacin is limited by its extremely high plasma 
protein binding although there might be also an efflux system involved. However, as 
discussed above, the use of the total brain to total plasma concentration ratio has its own 
limitations in the evaluation of CNS permeation. On the contrary, the CSF is often regarded 
as almost protein-free which makes the CSF to plasma ratio – and the evaluation of CSF 
permeation more accurate. However, the CSF concentration of a compound is not necessarily 
equal to the concentration in the brain parenchyma as they are regarded as two distinct 
compartments (de Lange and Danhof 2002). 
 
   The constant in vivo infusion method and the in situ brain perfusion method in rats proved 
to be very useful in the determination of CNS permeation. With slight modifications, a broad 
range of information can be obtained using these techniques, including the evaluation of the 
effect of efflux inhibitors and plasma protein binding on the brain permeation of compounds. 
The incorporation of the determination of unbound drug concentrations both in plasma and in 
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brain tissue would make these models extremely accurate. The determination of ibuprofen, 
indomethacin and ketoprofen from brain tissue homogenate, CSF, plasma and protein-free 
plasma was conducted by using several sample pre-treatment and analytical methods. In 
particular, the low drug concentrations in the human CSF and in the protein-free plasma 
demand extreme sensitivity from the assay methods. The significance of the sensitive 
analytical methods is likely to increase if the CNS permeation of compounds is to be 
determined by assaying the unbound concentrations in plasma, CSF and brain tissue.  
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7 CONCLUSIONS 
   In the present study, the CNS permeation of three traditional NSAIDs ibuprofen, 
indomethacin and ketoprofen was evaluated. The following conclusions can be made: 
 
- Ibuprofen and indomethacin permeated poorly into the rat CNS after intravenous 
administration, as indicated by the low total brain to total plasma concentration ratio of 0.02 
for ibuprofen and 0.01 for indomethacin. The unbound fraction of indomethacin permeated 
quite readily into the CNS during in situ brain perfusion and based on the total brain to 
unbound plasma concentration ratio after intravenous infusion. 
 
- The brain permeation of indomethacin could be increased by co-administration of 
probenecid. This suggests that brain permeation of indomethacin may be influenced by a 
probenecid-sensitive efflux mechanism. 
 
- An increase in the unbound fraction enhanced the brain permeation of indomethacin.  
 
- The CSF permeation of ketoprofen and indomethacin was limited after intravenous 
administration in children since only less than 1% of the plasma drug concentration was 
detected in the CSF. CSF to unbound plasma concentration ratios of ketoprofen were less than 
unity within the sampling period, whereas the majority of the CSF to unbound plasma 
concentration ratios of indomethacin were above unity. 
 
- Ketoprofen and indomethacin seem to have different rates of CSF entry, with indomethacin 
being able to pass across the BCSFB more readily than ketoprofen when evaluated by the 
time when the maximum CSF concentrations were observed. 
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